Drug Screening Market by Offering [On-site Testing, Rapid Testing (Urine, Oral), Analytical (Breathalyzer, Immunoassay, Chromatography)], Sample (Blood, Urine, Hair), Drug (Cannabis, Alcohol), End User (Workplace, Law, Hospitals) - Global Forecast to 2030

Market Size
$10.36B
MARKET SIZE, 2025
Projected Market Size
$21.29B
MARKET SIZE, 2030
CAGR
15.5%
CAGR (2025-2030)
Forecast Period
2025-2030
FORECAST PERIOD

OVERVIEW

drug-alcohol-screening-market Overview

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

The global drug screening market, valued at US$8.92 billion in 2024, stood at US$10.36 billion in 2025 and is projected to advance at a resilient CAGR of 15.5% from 2025 to 2030, culminating in a forecasted valuation of US$21.29 billion by the end of the period.

KEY TAKEAWAYS

  • MARKET SNAPSHOT:
    Base Year Market Size (2024): USD 8.92 Billion
    Current Market Size (2025): USD 10.36 Billion
    Forecast Market Size (2030): USD 21.29 Billion
    CAGR (2025–2030): 15.5%
  • SEGMENT LEADERSHIP:
    Regional Leader: North America accounted for the largest share of 48.0% of the global drug screening market in 2024.
    Service Leader: Services accounted for 58.8% of the drug screening market in 2024.
    Sample Type Leader: Oral fluid samples are projected to register the highest CAGR of 17.1% during the forecast period.
    Drug Type Leader: Cannabis is projected to register the highest growth in the drug screening market.
    End User Leader: Drug Testing Laboratories accounted for the largest share of the drug screening market in 2024.
  • MARKET OUTLOOK & COMPETITIVE LANDSCAPE:
    Labcorp, Quest Diagnostic Incorporated, and Abbott were identified as some of the star players in the global drug screening market, given their strong market share and product footprint.
    ACM Global Laboratories has distinguished itself among startups and SMEs by securing strong footholds in specialized niche areas, underscoring its potential as an emerging market leader.

The market for drug screening is being fueled by growing workplace and clinical testing programs, an increased need for opioid/polysubstance monitoring, and an increased use of rapid point-of-care technologies and advanced confirmatory testing (LC MS/MS) systems. However, factors such as false positives, chain-of-custody issues, and privacy concerns may hinder the marketplace.

TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS

The drug screening industry is currently undergoing a paradigm shift driven by the incorporation of rapid point-of-care analysis, highly sensitive confirmation procedures (LC-MS/MS technology), and automation in laboratory processing for drug screenings carried out at the workplace and in health and forensic settings. Some of the new trends, namely oral fluid testing, expanded opiate drug panels for fentanyl variants, and cloud-assisted chain-of-custody solutions for reporting, are working to increase the speed & scalability of the process while also eliminating the risks associated with tampering with results. There also appears to be a rising emphasis on the aspect of compliance, privacy, and result integrity, which requires laboratories and service deliverers to upgrade their infrastructure and quality processes.

drug-alcohol-screening-market Disruptions

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

MARKET DYNAMICS

Drivers
Impact
Level
  • Growing consumption of illicit drugs and alcohol
  • Enforcement of stringent laws mandating drug and alcohol testing
RESTRAINTS
Impact
Level
  • Ban on alcohol consumption in Islamic countries
  • Prohibition on workplace drug testing
OPPORTUNITIES
Impact
Level
  • Popularity of oral fluid testing
  • Introduction of fingerprint-based drug testing at workplaces
CHALLENGES
Impact
Level
  • Accuracy and specificity concerns in breathalyzers
  • False positive and negative results in drug screening

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

Driver: Growing consumption of illicit drugs and alcohol

With the increase in drug abuse and the overall health concern that comes with addiction, more screening for drug and alcohol abuse is being conducted by the government, the business community, and the healthcare industry. The main driver for the growth of the drug screening industry is the overall rise in the abuse of illicit drugs and alcohol, which means that more screenings are being conducted in hospitals, rehab facilities, and law enforcement organizations for rapid clinical decision-making and risk prevention. Furthermore, the overall rise in the abuse of many substances and the potency of the substances being used is resulting in the overall need for extended drug panels and more screenings for the accurate identification of abuse cases. Overall, the drug screening industry is driven by the overall need for the monitoring of abuse and the overall prevention of accidents and the effects associated with drug and alcohol abuse that affect the community as a whole.

Restraint: Ban on alcohol consumption in Islamic countries

As consumption of alcohol is forbidden or restricted in many Islamic countries, the demand for alcohol screening and related testing services is substantially limited. The implementation of government policies to enforce a ban on alcohol production, sale, and consumption reduces the need for routine alcohol screenings across workplaces, healthcare facilities, and law enforcement settings. In addition, lower reported alcohol usage limits large-scale preventive screening programs, especially in occupational health and public safety applications. Accordingly, the overall scope for alcohol testing under drug screening panels is limited.

Opportunity: Popularity of oral fluid testing

The increasing use of oral fluid testing creates a strong opportunity for the drug screening industry, as there is a greater demand from organizations for rapid, non-invasive & efficient procedures for screening. Oral fluid collection facilitates direct observation, making it less vulnerable to adulteration or substitution than urine tests. Moreover, rapid testing for recent use through oral fluid testing is also important for post-incident, reasonable suspicion, or roadside testing, which require decision support in near-real-time environments. The growing adoption of advanced oral fluid tests is also making this product more attractive, driving greater use and, in turn, fueling industry growth.

Challenge: Accuracy and specificity concerns in breathalyzers

One of the major challenges in the drug screening industry concerns the accuracy, specificity, and legal defensibility of breath analyzers, particularly those tests that must be legally defensible in court. Breath alcohol, in fact, can be affected in a variety of ways, including device calibration errors, sample collection techniques, environmental factors, and individual physiology, which can all contribute to questionable results. Further, breath alcohol detectors are only effective at detecting use of the substance short of a test period prior to analysis, as opposed to levels of intoxication, thereby restricting use in a variety of applications that require high-level enforcement action. These issues require more frequent confirmatory laboratory testing and more stringent quality control, thereby increasing time and operational complexity. Limitations in accuracy and challenges with specificity can restrain the wider acceptance and confidence in screening programs based on breathalyzers.

DRUG SCREENING MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES

COMPANY USE CASE DESCRIPTION BENEFITS
Comprehensive drug screening + confirmatory testing services supporting workplace compliance and clinical monitoring Broad test menu, consistent chain-of-custody, improved compliance readiness
Large-scale drug testing services for employers, healthcare providers, and government agencies (pre-employment, random, post-accident) Nationwide access, reliable reporting, scalable testing volumes
Rapid drug-of-abuse screening solutions used in emergency departments, clinics, and workplace programs for quick preliminary detection Faster decision-making, immediate triage support, reduced delays in care and safety actions
Oral fluid-based collection devices and screening solutions for workplace and forensic testing Non-invasive collection, reduced tampering, easier on-site sample capture
LC-MS/MS confirmatory drug testing platforms for forensic and clinical toxicology labs (high sensitivity drug identification) Higher specificity, reduced false positives, legally defensible results

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

MARKET ECOSYSTEM

The drug screening market ecosystem comprises leading testing technology and service providers such as Labcorp, Quest Diagnostics, Abbott, Thermo Fisher Scientific, Roche, Siemens Healthineers, Shimadzu, OraSure Technologies, Dräger, Premier Biotech, Psychemedics, and Omega Laboratories, which deliver rapid screening kits, oral fluid collection systems, confirmatory LC-MS/MS platforms, and high-throughput laboratory testing services. Workplace- and compliance-focused players such as CareHealth America and AccuSourceHR, along with specialized providers such as LifeLoc Technologies and Intoximeters, support program execution through breath alcohol testing and field-ready screening solutions. Regulatory bodies such as the US FDA, SAMHSA, and the US Department of Transportation (DOT) ensure testing standardization, result integrity, and compliance across applications. End users, including drug testing laboratories, workplaces, hospitals, pain management centers, and criminal justice and law enforcement agencies, adopt these solutions to improve workplace safety, enable clinical monitoring, and strengthen regulatory enforcement. Collaboration across manufacturers, labs, and regulators is accelerating innovation in oral fluid testing, expanded drug panels, and digital chain-of-custody reporting, driving overall market growth.

drug-alcohol-screening-market Ecosystem

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

MARKET SEGMENTS

drug-alcohol-screening-market Segments

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

Drug Screening Market, By Offering

The services segment dominates the drug screening market because employers, healthcare organizations, and forensic departments are increasingly outsourcing end-to-end drug testing operations to achieve quicker turnaround times and consistent reporting and compliance requirements. There is an increasing tendency among organizations to outsource specialized drug testing services, which in turn eliminates internal logistical requirements and ensures that accuracy and quality standards are maintained in drug test results. The increasing trend of drug testing in the workplace, particularly in safety-sensitive work environments, and also in response to increasing demand for drug testing in a random and post-incident manner, is also boosting service adoption. The inclusion of reporting technology and program management functionality is also making drug screening operations more efficient.

Drug Screening Market, By Sample Type

The urine samples segment accounted for the leading share of the drug screening market in 2024, thanks to its widespread acceptance as the preferred biological specimen for workplace, clinical, and forensic applications. This type of test is widely preferred for its excellent cost-effectiveness and high detectability. It is also much less complex than blood or saliva tests, which involve the use of highly sophisticated systems to conduct testing. The results offer an excellent cost-versus-performance ratio. The segment also benefits from standardized procedures for testing and confirmation. This makes it simpler to implement on a mass scale. Additionally, it provides rapid point-of-care test kits and laboratory confirmation tests.

Drug Screening Market, By Drug Type

The cannabis segment is projected to witness significant growth in the drug screening market because of its high usage rate among people from different age groups and its increased relevance in workplace, clinical, and forensic drug screening programs. Moreover, despite changes in drug legalization policies in different regions and countries, cannabis remains a substance that is largely monitored because it can affect cognitive functions and reaction times, especially in safety-sensitive jobs. Additionally, the increased popularity of workplace drug screening and drug screening in emergency and rehabilitation centers continues to ensure its position in the overall market. The easy availability and use of proven drug screening techniques, including immunoassays and confirmatory laboratory tests in urine, continue to ensure that this category holds a leading share in the market.

Drug Screening Market, By End User

The drug testing laboratories segment accounted for the largest share of the drug screening market due to their ability to generate high-throughput, standardized, legally defensible results in the workplace and in clinical & forensic environments. These laboratories remain highly in demand due to their easy access to sophisticated analytical instruments and confirmatory testing, which help accurately detect drugs, even at trace levels. Moreover, drug testing laboratories remain at the forefront in dealing with the management of drug screening programs on a larger scale in the workplace, government, and medical settings, providing comprehensive services such as sample processing, chain-of-custody management, medical review support, and secure web reporting through their overall expertise in drug testing and safety profiling.

REGION

Asia Pacific to register highest CAGR in drug screening market during forecast period (2024-2029)

Asia Pacific is expected to register the highest growth in the drug screening market due to rising concerns about drug abuse, strengthened workplace safety regulations, and increased healthcare infrastructure spending in major emerging nations, such as China, India, Japan, South Korea, and Southeast Asia. The rapid pace of industrialization in Asia, along with the growing focus on workplace safety in industries such as manufacturing, mining, construction, logistics, and air transport, is also driving companies to implement drug testing.

drug-alcohol-screening-market Region

DRUG SCREENING MARKET: COMPANY EVALUATION MATRIX

Labcorp (Star) is one of the major players in the market for drug testing, mainly because of its scope of laboratory testing and toxicology services. Another major player entering the drug testing realm is F. Hoffmann-La Roche Ltd. (Emerging Player). These companies are poised to enhance their positions by leveraging new technologies to use immunoassays as a platform for speedy, accurate drug testing. Even though Labcorp is a major player in the drug screening segment of the testing industry due to its scale and scope, it can face competition from other players.

drug-alcohol-screening-market Evaluation Metrics

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

KEY MARKET PLAYERS

MARKET SCOPE

REPORT METRIC DETAILS
Market Size in 2024 (Value) USD 8.92 BN
Market Forecast in 2030 (Value) USD 21.9 BN
Growth Rate 15.50%
Years Considered 2023–2030
Base Year 2024
Forecast Period 2025–2030
Units Considered Value (USD Billion)
Report Coverage Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Segments Covered
  • By Offering:
    • Services
    • Products
  • By Sample Type:
    • Urine Samples
    • Breath Samples
    • Oral Fluid Samples
    • Hair Samples
    • Other Samples
  • By Drug Type:
    • Cannabis
    • Alcohol
    • Cocaine
    • Opioids
    • Amphetamine & Meth amphetamine
    • Other Drugs
  • By End User:
    • Healthcare Providers
    • Healthcare Payers
    • Life Sciences Industry
Regions Covered North America, Asia Pacific, Europe, Latin America, Middle East & Africa

WHAT IS IN IT FOR YOU: DRUG SCREENING MARKET REPORT CONTENT GUIDE

drug-alcohol-screening-market Content Guide

DELIVERED CUSTOMIZATIONS

We have successfully delivered the following deep-dive customizations:

CLIENT REQUEST CUSTOMIZATION DELIVERED VALUE ADDS
Region-Specific Drug Screening Market Scope (Australia and New Zealand) Delivered an integrated customization covering rapid testing devices market sizing (Australia & New Zealand), regulatory landscape assessment, and competitive analysis of 3–5 key players operating across Australia and New Zealand Enabled focused investment decisions, improved vendor benchmarking and partnership strategy, and supported market-entry prioritization based on opportunity size and regulatory requirements

RECENT DEVELOPMENTS

  • September 2025 : LabCorp announced a collaboration with Roche to adopt FDA-cleared digital pathology slide scanners, advancing digital pathology workflows that improve diagnostic efficiency, accuracy, and AI integration across LabCorp’s laboratory services.
  • March 2025 : LabCorp (US) acquired select oncology and related clinical testing service assets from BioReference Health, enhancing its laboratory services network and expanding customers’ access to comprehensive diagnostic testing.
  • November 2024 : Quest Diagnostic Incorporated introduced definitive urine drug monitoring panels that detect 113 drugs and volatile compounds, respectively, improving clinical toxicology workflows in emergency and baseline assessments and supporting acute poisoning identification with high specificity and confirmatory precision.

 

Table of Contents

checkmarkExclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE
PAGE NO
1
INTRODUCTION
 
 
 
 
 
39
2
EXECUTIVE SUMMARY
 
 
 
 
 
45
3
PREMIUM INSIGHTS
 
 
 
 
 
50
4
MARKET OVERVIEW
Regulatory shifts spark innovation in drug testing, with emerging economies offering lucrative growth prospects.
 
 
 
 
 
53
 
4.1
INTRODUCTION
 
 
 
 
 
 
4.2
MARKET DYNAMICS
 
 
 
 
 
 
 
4.2.1
DRIVERS
 
 
 
 
 
 
 
4.2.1.1
GROWING CONSUMPTION OF ILLICIT DRUGS AND ALCOHOL
 
 
 
 
 
 
4.2.1.2
ENFORCEMENT OF STRINGENT LAWS MANDATING DRUG AND ALCOHOL TESTING
 
 
 
 
 
 
4.2.1.3
INCREASING NUMBER OF REGULATORY APPROVALS FOR DRUG SCREENING PRODUCTS & SERVICES
 
 
 
 
 
4.2.2
RESTRAINTS
 
 
 
 
 
 
 
4.2.2.1
BAN ON ALCOHOL CONSUMPTION IN ISLAMIC COUNTRIES
 
 
 
 
 
 
4.2.2.2
PROHIBITION ON WORKPLACE DRUG TESTING
 
 
 
 
 
4.2.3
OPPORTUNITIES
 
 
 
 
 
 
 
4.2.3.1
POPULARITY OF ORAL FLUID TESTING
 
 
 
 
 
 
4.2.3.2
INTRODUCTION OF FINGERPRINT-BASED DRUG TESTING IN WORKPLACES
 
 
 
 
 
 
4.2.3.3
HIGH GROWTH OPPORTUNITIES IN EMERGING ECONOMIES
 
 
 
 
 
4.2.4
CHALLENGES
 
 
 
 
 
 
 
4.2.4.1
ACCURACY AND SPECIFICITY CONCERNS IN BREATHALYZERS
 
 
 
 
 
 
4.2.4.2
FALSE POSITIVE AND NEGATIVE RESULTS IN DRUG SCREENING
 
 
 
 
4.3
UNMET NEEDS & WHITE SPACES
 
 
 
 
 
 
4.4
INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
 
 
 
 
 
 
4.5
STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
 
 
 
 
 
5
INDUSTRY TRENDS
Navigate evolving healthcare IT trends to capitalize on emerging market opportunities and competitive dynamics.
 
 
 
 
 
63
 
5.1
PORTER’S FIVE FORCES ANALYSIS
 
 
 
 
 
 
 
5.1.1
BARGAINING POWER OF SUPPLIERS
 
 
 
 
 
 
5.1.2
BARGAINING POWER OF BUYERS
 
 
 
 
 
 
5.1.3
THREAT OF SUBSTITUTES
 
 
 
 
 
 
5.1.4
THREAT OF NEW ENTRANTS
 
 
 
 
 
 
5.1.5
INTENSITY OF COMPETITIVE RIVALRY
 
 
 
 
 
5.2
MACROECONOMIC INDICATORS
 
 
 
 
 
 
 
5.2.1
INTRODUCTION
 
 
 
 
 
 
5.2.2
GDP TRENDS & FORECAST
 
 
 
 
 
 
5.2.3
TRENDS IN GLOBAL HEALTHCARE IT INDUSTRY
 
 
 
 
 
5.3
VALUE CHAIN ANALYSIS
 
 
 
 
 
 
 
5.4
ECOSYSTEM ANALYSIS
 
 
 
 
 
 
 
5.5
PRICING ANALYSIS
 
 
 
 
 
 
 
 
5.5.1
INDICATIVE PRICING OF DRUG SCREENING PRODUCTS & SERVICES, BY TYPE (2024)
 
 
 
 
 
 
5.5.2
INDICATIVE PRICING OF DRUG SCREENING PRODUCTS & SERVICES, BY REGION (2024)
 
 
 
 
 
5.6
KEY CONFERENCES & EVENTS, 2026–2027
 
 
 
 
 
 
5.7
TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
 
 
 
 
 
 
5.8
INVESTMENT & FUNDING SCENARIO
 
 
 
 
 
 
 
5.9
CASE STUDY ANALYSIS
 
 
 
 
 
 
5.10
IMPACT OF 2025 US TARIFFS ON DRUG SCREENING MARKET
 
 
 
 
 
 
 
 
5.10.1
INTRODUCTION
 
 
 
 
 
 
5.10.2
KEY TARIFF RATES
 
 
 
 
 
 
5.10.3
PRICE IMPACT ANALYSIS
 
 
 
 
 
 
5.10.4
IMPACT ON COUNTRY/REGION
 
 
 
 
 
 
 
5.10.4.1
US
 
 
 
 
 
 
5.10.4.2
EUROPE
 
 
 
 
 
 
5.10.4.3
ASIA PACIFIC
 
 
 
 
 
5.10.5
IMPACT ON END-USE INDUSTRIES
 
 
 
 
 
 
 
5.10.5.1
DRUG TESTING LABORATORIES
 
 
 
 
 
 
5.10.5.2
WORKPLACES
 
 
 
 
 
 
5.10.5.3
CRIMINAL JUSTICE SYSTEMS & LAW ENFORCEMENT AGENCIES
 
 
 
 
 
 
5.10.5.4
HOSPITALS
 
 
 
 
 
 
5.10.5.5
DRUG TREATMENT CENTERS
 
 
 
 
 
 
5.10.5.6
INDIVIDUAL USERS
 
 
 
 
 
 
5.10.5.7
PAIN MANAGEMENT CENTERS
 
 
 
 
 
 
5.10.5.8
SCHOOLS & COLLEGES
 
 
 
 
 
 
5.10.5.9
OTHER END USERS
 
 
 
6
STRATEGIC DISRUPTIONS THROUGH TECHNOLOGY, PATENTS, AND DIGITAL & AI ADOPTION
Harness AI and emerging tech for transformative drug screening and predictive monitoring advancements.
 
 
 
 
 
82
 
6.1
KEY EMERGING TECHNOLOGIES
 
 
 
 
 
 
 
6.1.1
LC-MS/MS & GC-MS-BASED CONFIRMATORY TESTING TECHNOLOGIES
 
 
 
 
 
 
6.1.2
AI-DRIVEN RESULT INTERPRETATION & QUALITY ASSURANCE TECHNOLOGIES
 
 
 
 
 
 
6.1.3
LABORATORY AUTOMATION & ROBOTICS TECHNOLOGIES
 
 
 
 
 
6.2
COMPLEMENTARY TECHNOLOGIES
 
 
 
 
 
 
 
6.2.1
MOBILE HEALTH (MHEALTH) & REMOTE COLLECTION TECHNOLOGIES
 
 
 
 
 
 
6.2.2
ANALYTICS & POPULATION-LEVEL DRUG USE SURVEILLANCE TOOLS
 
 
 
 
 
6.3
ADJACENT TECHNOLOGIES
 
 
 
 
 
 
 
6.3.1
FORENSIC CASE MANAGEMENT SYSTEMS
 
 
 
 
 
 
6.3.2
WORKFORCE BACKGROUND SCREENING/VERIFICATION SYSTEMS
 
 
 
 
 
6.4
TECHNOLOGY/PRODUCT ROADMAP
 
 
 
 
 
 
6.5
PATENT ANALYSIS
 
 
 
 
 
 
 
 
6.5.1
PATENT PUBLICATION TRENDS FOR DRUG SCREENING MARKET
 
 
 
 
 
 
6.5.2
INSIGHTS: JURISDICTION & TOP APPLICANT ANALYSIS
 
 
 
 
 
6.6
FUTURE APPLICATIONS
 
 
 
 
 
 
 
6.6.1
AI-ENABLED INTELLIGENT SCREENING AND RESULT INTERPRETATION
 
 
 
 
 
 
6.6.2
CONTINUOUS AND PREDICTIVE DRUG MONITORING APPLICATIONS
 
 
 
 
 
 
6.6.3
DECENTRALIZED, AT-HOME, AND POINT-OF-CARE SCREENING EXPANSION
 
 
 
 
 
 
6.6.4
INTEGRATED COMPLIANCE, FORENSIC, AND PUBLIC HEALTH INTELLIGENCE PLATFORMS
 
 
 
 
 
 
6.6.5
PERSONALIZED AND THERAPEUTIC DRUG SCREENING APPLICATIONS
 
 
 
 
 
6.7
IMPACT OF AI/GEN AI ON DRUG SCREENING MARKET
 
 
 
 
 
 
 
 
6.7.1
INTRODUCTION
 
 
 
 
 
 
6.7.2
MARKET POTENTIAL OF AI/GEN AI IN DRUG SCREENING MARKET
 
 
 
 
 
 
6.7.3
CASE STUDIES RELATED TO AI/GEN AI IMPLEMENTATION
 
 
 
 
 
 
 
6.7.3.1
AI-DRIVEN TRANSFORMATION OF PRECLINICAL TOXICOLOGY SCREENING AT PATHAI
 
 
 
 
 
6.7.4
IMPACT OF AI/GEN AI ON INTERCONNECTED & ADJACENT ECOSYSTEMS
 
 
 
 
 
 
 
6.7.4.1
LABORATORY & TOXICOLOGY OPERATIONS
 
 
 
 
 
 
6.7.4.2
LABORATORY INFORMATION SYSTEMS (LIS) & COMPLIANCE INFRASTRUCTURE
 
 
 
 
 
 
6.7.4.3
CLINICAL CARE, WORKPLACE SAFETY, AND MONITORING PROGRAMS
 
 
 
 
 
6.7.5
USER READINESS AND IMPACT ASSESSMENT
 
 
 
 
 
 
 
6.7.5.1
USER READINESS
 
 
 
 
 
 
 
 
6.7.5.1.1
USER A: CLINICAL, REFERENCE, AND TOXICOLOGY LABORATORIES
 
 
 
 
 
 
6.7.5.1.2
USER B: HEALTHCARE PROVIDERS, EMPLOYERS, AND FORENSIC AGENCIES
 
 
 
 
6.7.5.2
IMPACT ASSESSMENT
 
 
 
 
 
 
 
 
6.7.5.2.1
USER A: CLINICAL, REFERENCE, AND TOXICOLOGY LABORATORIES
 
 
 
 
 
 
6.7.5.2.2
USER B: HEALTHCARE PROVIDERS, EMPLOYERS, AND FORENSIC AGENCIES
 
7
CUSTOMER LANDSCAPE & BUYER BEHAVIOR
Unlock key buyer insights and unmet needs driving market profitability and decision-making dynamics.
 
 
 
 
 
98
 
7.1
INTRODUCTION
 
 
 
 
 
 
7.2
DECISION-MAKING PROCESS
 
 
 
 
 
 
7.3
BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA
 
 
 
 
 
 
 
7.3.1
KEY STAKEHOLDERS IN BUYING PROCESS
 
 
 
 
 
 
7.3.2
BUYING CRITERIA
 
 
 
 
 
7.4
ADOPTION BARRIERS & INTERNAL CHALLENGES
 
 
 
 
 
 
7.5
UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
 
 
 
 
 
 
 
7.5.1
UNMET NEEDS
 
 
 
 
 
 
7.5.2
END-USER EXPECTATIONS
 
 
 
 
 
7.6
MARKET PROFITABILITY
 
 
 
 
 
8
REGULATORY LANDSCAPE
Navigate complex global regulations with region-specific insights and compliance frameworks.
 
 
 
 
 
105
 
8.1
REGIONAL REGULATIONS & COMPLIANCE
 
 
 
 
 
 
 
8.1.1
REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
 
8.1.2
REGULATORY FRAMEWORK
 
 
 
 
 
 
 
8.1.2.1
NORTH AMERICA
 
 
 
 
 
 
8.1.2.2
EUROPE
 
 
 
 
 
 
8.1.2.3
ASIA PACIFIC
 
 
 
 
 
 
8.1.2.4
LATIN AMERICA
 
 
 
 
 
 
8.1.2.5
MIDDLE EAST & AFRICA
 
 
 
 
 
8.1.3
INDUSTRY STANDARDS
 
 
 
 
9
DRUG SCREENING MARKET, BY OFFERING
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 35 Data Tables
 
 
 
 
 
113
 
9.1
INTRODUCTION
 
 
 
 
 
 
9.2
SERVICES
 
 
 
 
 
 
 
9.2.1
WORKFORCE DECENTRALIZATION, PANEL COMPLEXITY, AND LITIGATION-READY TESTING TO DRIVE SUSTAINED MARKET GROWTH
 
 
 
 
 
 
9.2.2
LABORATORY TESTING SERVICES
 
 
 
 
 
 
 
9.2.2.1
ABILITY TO ENSURE ANALYTICAL RIGOR AND COMPLIANCE WITH REGULATORY STANDARDS TO DRIVE DEMAND
 
 
 
 
 
9.2.3
ON-SITE TESTING SERVICES
 
 
 
 
 
 
 
9.2.3.1
ABILITY TO DELIVER RAPID, POINT-OF-CARE SCREENING SOLUTIONS TO DRIVE MARKET GROWTH
 
 
 
 
9.3
PRODUCTS
 
 
 
 
 
 
 
9.3.1
ANALYTICAL INSTRUMENTS MARKET, BY TYPE
 
 
 
 
 
 
 
9.3.1.1
BREATHALYZERS
 
 
 
 
 
 
 
 
9.3.1.1.1
FUEL-CELL BREATHALYZERS
 
 
 
 
 
 
9.3.1.1.2
SEMICONDUCTOR BREATHALYZERS
 
 
 
 
 
 
9.3.1.1.3
OTHER BREATHALYZERS
 
 
 
 
9.3.1.2
IMMUNOASSAY ANALYZERS
 
 
 
 
 
 
 
 
9.3.1.2.1
GROWING ADOPTION OF HIGH-THROUGHPUT IMMUNOASSAY PLATFORMS TO POWER MODERN TOXICOLOGY
 
 
 
 
9.3.1.3
CHROMATOGRAPHY INSTRUMENTS
 
 
 
 
 
 
 
 
9.3.1.3.1
ADVANTAGES SUCH AS PRECISE, HIGH-SENSITIVITY ANALYSIS IN FORENSIC, CLINICAL, AND REGULATORY LABORATORIES TO FUEL GROWTH
 
 
 
9.3.2
ANALYTICAL INSTRUMENTS MARKET, BY MODALITY
 
 
 
 
 
 
 
9.3.2.1
HANDHELD BREATHALYZERS
 
 
 
 
 
 
 
 
9.3.2.1.1
CRITICAL ROLE IN DELIVERING FAST, ACCURATE, AND PORTABLE ALCOHOL SCREENING TO SUPPORT MARKET GROWTH
 
 
 
 
9.3.2.2
BENCHTOP BREATHALYZERS
 
 
 
 
 
 
 
 
9.3.2.2.1
GROWING USE OF BENCHTOP BREATHALYZERS FOR DRUG DETECTION ANALYSIS TO DRIVE GROWTH
 
 
 
9.3.3
RAPID TESTING DEVICES
 
 
 
 
 
 
 
9.3.3.1
URINE TESTING DEVICES
 
 
 
 
 
 
 
 
9.3.3.1.1
DRUG TESTING CUPS
 
 
 
 
 
 
9.3.3.1.2
DIP CARDS
 
 
 
 
 
 
9.3.3.1.3
DRUG TESTING CASSETTES
 
 
 
 
9.3.3.2
ORAL FLUID TESTING DEVICES
 
 
 
 
 
 
 
 
9.3.3.2.1
RAPID, NON-INVASIVE DETECTION OF RECENT DRUG USE ACROSS WORKPLACE, CLINICAL, AND LAW ENFORCEMENT SETTINGS TO FUEL GROWTH
 
 
 
9.3.4
CONSUMABLES
 
 
 
 
 
 
 
9.3.4.1
ASSAY KITS
 
 
 
 
 
 
 
 
9.3.4.1.1
RAPID, COST-EFFECTIVE, AND HIGH-THROUGHPUT SCREENING ACROSS DRUG TESTING APPLICATIONS TO DRIVE MARKET
 
 
 
 
9.3.4.2
SAMPLE COLLECTION DEVICES
 
 
 
 
 
 
 
 
9.3.4.2.1
RELIABLE, TAMPER-RESISTANT, AND VERSATILE DRUG TESTING ACROSS SETTINGS TO SUPPORT GROWTH
 
 
 
 
9.3.4.3
CALIBRATORS & CONTROLS
 
 
 
 
 
 
 
 
9.3.4.3.1
ABILITY TO VERIFY ACCURACY, PRECISION, AND RELIABILITY OF SCREENING AND CONFIRMATORY TEST RESULTS TO DRIVE GROWTH
 
 
 
 
9.3.4.4
OTHER CONSUMABLES
 
 
 
10
DRUG SCREENING MARKET, BY SAMPLE TYPE
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 11 Data Tables
 
 
 
 
 
142
 
10.1
INTRODUCTION
 
 
 
 
 
 
10.2
URINE SAMPLES
 
 
 
 
 
 
 
10.2.1
RECENT ADVANCES TO STRENGTHEN ACCURACY AND RELIABILITY IN URINE DRUG TESTING
 
 
 
 
 
10.3
BREATH SAMPLES
 
 
 
 
 
 
 
10.3.1
BREATH ALCOHOL TESTS TO REGISTER WIDE USAGE IN WORKPLACE TESTING AND LAW ENFORCEMENT APPLICATIONS
 
 
 
 
 
10.4
ORAL FLUID SAMPLES
 
 
 
 
 
 
 
10.4.1
NON-INVASIVE SAMPLE COLLECTION AND LOW CHANCE OF ADULTERATION TO SUPPORT USAGE OF ORAL FLUID SAMPLES
 
 
 
 
 
10.5
HAIR SAMPLES
 
 
 
 
 
 
 
10.5.1
ABILITY OF HAIR SAMPLES TO PROVIDE INSIGHTS INTO LONG-TERM DRUG USE TO BOOST MARKET
 
 
 
 
 
10.6
OTHER SAMPLES
 
 
 
 
 
11
DRUG SCREENING MARKET, BY DRUG TYPE
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 13 Data Tables
 
 
 
 
 
150
 
11.1
INTRODUCTION
 
 
 
 
 
 
11.2
CANNABIS
 
 
 
 
 
 
 
11.2.1
GROWING CANNABIS USE AND REGULATORY COMPLEXITY TO DRIVE SUSTAINED DEMAND FOR DRUG SCREENING SOLUTIONS
 
 
 
 
 
11.3
ALCOHOL
 
 
 
 
 
 
 
11.3.1
REGULATORY ENFORCEMENT AND TECHNOLOGY INNOVATION TO STRENGTHEN ALCOHOL SCREENING ADOPTION
 
 
 
 
 
11.4
COCAINE
 
 
 
 
 
 
 
11.4.1
SHIFT TOWARD RAPID, DEFENSIBLE DETECTION TO POSITION COCAINE AS PRIORITY DRUG IN MODERN SCREENING PANELS
 
 
 
 
 
11.5
OPIOIDS
 
 
 
 
 
 
 
11.5.1
EXPANDED OPIOID PANELS AND ADVANCED CONFIRMATORY TECHNOLOGIES TO REINFORCE OPIOID SCREENING AS HIGH PRIORITY
 
 
 
 
 
11.6
AMPHETAMINES & METHAMPHETAMINES
 
 
 
 
 
 
 
11.6.1
ADVANCED ANALYTICS AND DIFFERENTIATION TESTING TO REDEFINE AMPHETAMINE & METHAMPHETAMINE DETECTION
 
 
 
 
 
11.7
OTHER DRUGS
 
 
 
 
 
12
DRUG SCREENING MARKET, BY END USER
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 20 Data Tables
 
 
 
 
 
161
 
12.1
INTRODUCTION
 
 
 
 
 
 
12.2
DRUG TESTING LABORATORIES
 
 
 
 
 
 
 
12.2.1
ADVANCED ANALYTICS, AUTOMATION, AND EXPANDING FORENSIC AND CLINICAL DEMAND TO DRIVE MARKET GROWTH
 
 
 
 
 
12.3
WORKPLACES
 
 
 
 
 
 
 
12.3.1
RISING NUMBER OF DRUG ABUSE CASES TO INCREASE WORKPLACE TESTING
 
 
 
 
 
12.4
CRIMINAL JUSTICE SYSTEMS & LAW ENFORCEMENT AGENCIES
 
 
 
 
 
 
 
12.4.1
HIGH SUBSTANCE-USE PREVALENCE AND DUI RISKS TO DRIVE MANDATORY DRUG & ALCOHOL TESTING
 
 
 
 
 
12.5
HOSPITALS
 
 
 
 
 
 
 
12.5.1
RISING EMERGENCY ADMISSIONS, OPIOID OVERDOSES, AND PATIENT SAFETY MANDATES TO DRIVE STRONG DEMAND
 
 
 
 
 
12.6
DRUG TREATMENT CENTERS
 
 
 
 
 
 
 
12.6.1
RISING ADOPTION OF MEDICATION-ASSISTED TREATMENT, RELAPSE MONITORING, AND FENTANYL DETECTION TO DRIVE DEMAND
 
 
 
 
 
12.7
INDIVIDUAL USERS
 
 
 
 
 
 
 
12.7.1
GROWING SELF-MONITORING, HOME TESTING, AND RECOVERY ACCOUNTABILITY TO EXPANDING INDIVIDUAL USE OF SCREENING
 
 
 
 
 
12.8
PAIN MANAGEMENT CENTERS
 
 
 
 
 
 
 
12.8.1
OPIOID PRESCRIBING OVERSIGHT AND PATIENT SAFETY MANDATES TO DRIVE INCREASED DRUG SCREENING
 
 
 
 
 
12.9
SCHOOLS & COLLEGES
 
 
 
 
 
 
 
12.9.1
MODERN TESTING AND AWARENESS PROGRAMS TO STRENGTHEN DRUG ABUSE PREVENTION IN SCHOOLS & COLLEGES
 
 
 
 
 
12.10
OTHER END USERS
 
 
 
 
 
13
DRUG SCREENING MARKET, BY REGION
Comprehensive coverage of 8 Regions with country-level deep-dive of 17 Countries | 348 Data Tables.
 
 
 
 
 
175
 
13.1
INTRODUCTION
 
 
 
 
 
 
13.2
NORTH AMERICA
 
 
 
 
 
 
 
13.2.1
MACROECONOMIC OUTLOOK FOR NORTH AMERICA
 
 
 
 
 
 
13.2.2
US
 
 
 
 
 
 
 
13.2.2.1
REGULATORY ENFORCEMENT AND SUBSTANCE USE PREVALENCE DRIVE DRUG SCREENING MARKET IN US
 
 
 
 
 
13.2.3
CANADA
 
 
 
 
 
 
 
13.2.3.1
PUBLIC HEALTH SURVEILLANCE, CONSUMPTION TRENDS, AND ENFORCEMENT & TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET
 
 
 
 
13.3
EUROPE
 
 
 
 
 
 
 
13.3.1
MACROECONOMIC OUTLOOK FOR EUROPE
 
 
 
 
 
 
13.3.2
GERMANY
 
 
 
 
 
 
 
13.3.2.1
STRENGTHENING DRUG SCREENING ADOPTION THROUGH PUBLIC HEALTH POLICY AND TECHNOLOGICAL MODERNIZATION TO SUPPORT MARKET GROWTH
 
 
 
 
 
13.3.3
FRANCE
 
 
 
 
 
 
 
13.3.3.1
REGULATORY ENFORCEMENT, TRANSPORT SAFETY, AND FORENSIC MODERNIZATION TO SHAPE DRUG SCREENING MARKET
 
 
 
 
 
13.3.4
UK
 
 
 
 
 
 
 
13.3.4.1
COMMUNITY-EMBEDDED TESTING, CRIMINAL JUSTICE DEMAND, AND REAL-TIME DRUG SURVEILLANCE TO SHAPE UK DRUG SCREENING MARKET
 
 
 
 
 
13.3.5
ITALY
 
 
 
 
 
 
 
13.3.5.1
STRENGTHENING DRUG SCREENING MARKET THROUGH ROADSIDE ENFORCEMENT AND ANALYTICAL INNOVATION & INSTITUTIONAL CAPACITY
 
 
 
 
 
13.3.6
SPAIN
 
 
 
 
 
 
 
13.3.6.1
EXPANDING DRUG SCREENING ADOPTION THROUGH ROAD SAFETY PROGRAMS TO DRIVE MARKET GROWTH
 
 
 
 
 
13.3.7
REST OF EUROPE
 
 
 
 
 
13.4
ASIA PACIFIC
 
 
 
 
 
 
 
13.4.1
MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
 
 
 
 
 
 
13.4.2
CHINA
 
 
 
 
 
 
 
13.4.2.1
SYNTHETIC DRUG CONTROL AND PHARMACEUTICAL INNOVATION TO DRIVE DRUG SCREENING MARKET GROWTH
 
 
 
 
 
13.4.3
JAPAN
 
 
 
 
 
 
 
13.4.3.1
JAPAN’S AGING POPULATION AND ADVANCED DIGITAL INFRASTRUCTURE TO DRIVE RAPID ADOPTION
 
 
 
 
 
13.4.4
INDIA
 
 
 
 
 
 
 
13.4.4.1
ALCOHOL DOMINANCE, OPIOID MISUSE, AND INDIA’S ROLE AS GLOBAL PHARMACEUTICAL HUB TO DRIVE DRUG SCREENING MARKET GROWTH
 
 
 
 
 
13.4.5
AUSTRALIA
 
 
 
 
 
 
 
13.4.5.1
HARM-REDUCTION POLICY, WORKPLACE SAFETY REGULATION, AND ROADSIDE TESTING TO DRIVE DRUG SCREENING MARKET
 
 
 
 
 
13.4.6
SOUTH KOREA
 
 
 
 
 
 
 
13.4.6.1
ZERO-TOLERANCE DRUG POLICY, MANDATORY MILITARY SERVICE, AND FORENSIC-GRADE TESTING TO SHAPE DRUG SCREENING MARKET
 
 
 
 
 
13.4.7
REST OF ASIA PACIFIC
 
 
 
 
 
13.5
LATIN AMERICA
 
 
 
 
 
 
 
13.5.1
MACROECONOMIC OUTLOOK FOR LATIN AMERICA
 
 
 
 
 
 
13.5.2
BRAZIL
 
 
 
 
 
 
 
13.5.2.1
BRAZIL’S DRUG SCREENING MARKET TO EXPAND AMID ROAD SAFETY MANDATES, SUBSTANCE-USE BURDEN, AND REGULATORY ENFORCEMENT
 
 
 
 
 
13.5.3
MEXICO
 
 
 
 
 
 
 
13.5.3.1
MEXICO’S DRUG SCREENING MARKET SHAPED BY METHAMPHETAMINE PREVALENCE, CROSS-BORDER LABOR DYNAMICS, AND PUBLIC SAFETY ENFORCEMENT
 
 
 
 
 
13.5.4
REST OF LATIN AMERICA
 
 
 
 
 
13.6
MIDDLE EAST & AFRICA
 
 
 
 
 
 
 
13.6.1
MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
 
 
 
 
 
 
13.6.2
GCC COUNTRIES
 
 
 
 
 
 
 
13.6.2.1
SAUDI ARABIA
 
 
 
 
 
 
 
 
13.6.2.1.1
PUBLIC SAFETY, DIAGNOSTIC MODERNIZATION, AND EVOLVING CONSUMPTION PATTERNS TO BOOST MARKET
 
 
 
 
13.6.2.2
UAE
 
 
 
 
 
 
 
 
13.6.2.2.1
INTEGRATED SAFETY ENFORCEMENT, WORKPLACE TESTING, AND DIAGNOSTIC MODERNIZATION TO EXPAND MARKET IN UAE
 
 
 
 
13.6.2.3
REST OF GCC COUNTRIES
 
 
 
 
 
13.6.3
SOUTH AFRICA
 
 
 
 
 
 
 
13.6.3.1
RISING SUBSTANCE USE, WORKPLACE RISK MANAGEMENT, AND ADVANCED SCREENING CAPABILITIES TO FUEL MARKET GROWTH
 
 
 
 
 
13.6.4
REST OF MIDDLE EAST & AFRICA
 
 
 
 
14
COMPETITIVE LANDSCAPE
Discover top strategies and financial standings of dominant and emerging players in drug screening.
 
 
 
 
 
335
 
14.1
OVERVIEW
 
 
 
 
 
 
14.2
KEY PLAYER STRATEGIES/RIGHT TO WIN
 
 
 
 
 
 
 
14.2.1
OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN DRUG SCREENING MARKET
 
 
 
 
 
14.3
REVENUE ANALYSIS, 2020–2024
 
 
 
 
 
 
 
14.4
MARKET SHARE ANALYSIS, 2024
 
 
 
 
 
 
 
14.5
BRAND COMPARISON
 
 
 
 
 
 
 
14.6
COMPANY VALUATION & FINANCIAL METRICS
 
 
 
 
 
 
 
14.6.1
FINANCIAL METRICS
 
 
 
 
 
 
14.6.2
COMPANY VALUATION
 
 
 
 
 
14.7
COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
 
 
 
 
 
 
 
 
14.7.1
STARS
 
 
 
 
 
 
14.7.2
EMERGING LEADERS
 
 
 
 
 
 
14.7.3
PERVASIVE PLAYERS
 
 
 
 
 
 
14.7.4
PARTICIPANTS
 
 
 
 
 
 
14.7.5
COMPANY FOOTPRINT: KEY PLAYERS, 2024
 
 
 
 
 
 
 
14.7.5.1
COMPANY FOOTPRINT
 
 
 
 
 
 
14.7.5.2
REGION FOOTPRINT
 
 
 
 
 
 
14.7.5.3
OFFERING FOOTPRINT
 
 
 
 
 
 
14.7.5.4
SAMPLE TYPE FOOTPRINT
 
 
 
 
 
 
14.7.5.5
DRUG TYPE FOOTPRINT
 
 
 
 
 
 
14.7.5.6
END-USER FOOTPRINT
 
 
 
 
14.8
COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
 
 
 
 
 
 
 
 
14.8.1
PROGRESSIVE COMPANIES
 
 
 
 
 
 
14.8.2
RESPONSIVE COMPANIES
 
 
 
 
 
 
14.8.3
DYNAMIC COMPANIES
 
 
 
 
 
 
14.8.4
STARTING BLOCKS
 
 
 
 
 
 
14.8.5
COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
 
 
 
 
 
 
 
14.8.5.1
DETAILED LIST OF KEY STARTUPS/SMES
 
 
 
 
 
 
14.8.5.2
COMPETITIVE BENCHMARKING OF STARTUPS/SMES
 
 
 
 
14.9
COMPETITIVE SCENARIO
 
 
 
 
 
 
 
14.9.1
PRODUCT LAUNCHES & ENHANCEMENTS
 
 
 
 
 
 
14.9.2
DEALS
 
 
 
 
 
 
14.9.3
OTHER DEVELOPMENTS
 
 
 
 
15
COMPANY PROFILES
In-depth Company Profiles of Leading Market Players with detailed Business Overview, Product and Service Portfolio, Recent Developments, and Unique Analyst Perspective (MnM View)
 
 
 
 
 
358
 
15.1
KEY PLAYERS
 
 
 
 
 
 
 
15.1.1
LABCORP
 
 
 
 
 
 
 
15.1.1.1
BUSINESS OVERVIEW
 
 
 
 
 
 
15.1.1.2
PRODUCTS & SERVICES OFFERED
 
 
 
 
 
 
15.1.1.3
RECENT DEVELOPMENTS
 
 
 
 
 
 
 
 
15.1.1.3.1
DEALS
 
 
 
 
15.1.1.4
MNM VIEW
 
 
 
 
 
 
 
 
15.1.1.4.1
KEY STRENGTHS
 
 
 
 
 
 
15.1.1.4.2
STRATEGIC CHOICES
 
 
 
 
 
 
15.1.1.4.3
WEAKNESSES & COMPETITIVE THREATS
 
 
 
15.1.2
QUEST DIAGNOSTICS INCORPORATED
 
 
 
 
 
 
15.1.3
ABBOTT
 
 
 
 
 
 
15.1.4
ORASURE TECHNOLOGIES INC.
 
 
 
 
 
 
15.1.5
ALFA SCIENTIFIC DESIGNS INC.
 
 
 
 
 
 
15.1.6
THERMO FISHER SCIENTIFIC INC.
 
 
 
 
 
 
15.1.7
DRÄGERWERK AG & CO. KGAA
 
 
 
 
 
 
15.1.8
LIFELOC TECHNOLOGIES, INC.
 
 
 
 
 
 
15.1.9
MPD INC.
 
 
 
 
 
 
15.1.10
OMEGA LABORATORIES, INC.
 
 
 
 
 
 
15.1.11
PREMIER BIOTECH, INC.
 
 
 
 
 
 
15.1.12
PSYCHEMEDICS CORPORATION
 
 
 
 
 
 
15.1.13
F. HOFFMANN-LA ROCHE LTD.
 
 
 
 
 
 
15.1.14
SHIMADZU CORPORATION
 
 
 
 
 
 
15.1.15
SIEMENS HEALTHINEERS AG
 
 
 
 
 
 
15.1.16
BIO-RAD LABORATORIES, INC.
 
 
 
 
 
15.2
OTHER PLAYERS
 
 
 
 
 
 
 
15.2.1
CAREHEALTH AMERICA CORP.
 
 
 
 
 
 
15.2.2
ACCUSOURCEHR, INC.
 
 
 
 
 
 
15.2.3
CORDANT HEALTH SOLUTIONS
 
 
 
 
 
 
15.2.4
ADVACARE PHARMA
 
 
 
 
 
 
15.2.5
ACM GLOBAL LABORATORIES
 
 
 
 
 
 
15.2.6
MILLENNIUM HEALTH
 
 
 
 
 
 
15.2.7
CLINICAL REFERENCE LABORATORY, INC.
 
 
 
 
 
 
15.2.8
INTOXIMETERS
 
 
 
 
 
 
15.2.9
INTOXALOCK
 
 
 
 
16
RESEARCH METHODOLOGY
 
 
 
 
 
433
 
16.1
RESEARCH APPROACH
 
 
 
 
 
 
 
16.1.1
SECONDARY RESEARCH
 
 
 
 
 
 
 
16.1.1.1
KEY DATA FROM SECONDARY SOURCES
 
 
 
 
 
16.1.2
PRIMARY RESEARCH
 
 
 
 
 
 
 
16.1.2.1
PRIMARY SOURCES
 
 
 
 
 
 
16.1.2.2
KEY DATA FROM PRIMARY SOURCES
 
 
 
 
 
 
16.1.2.3
BREAKDOWN OF PRIMARIES
 
 
 
 
 
 
16.1.2.4
INSIGHTS FROM PRIMARY EXPERTS
 
 
 
 
16.2
RESEARCH METHODOLOGY DESIGN
 
 
 
 
 
 
16.3
MARKET SIZE ESTIMATION
 
 
 
 
 
 
16.4
MARKET BREAKDOWN & DATA TRIANGULATION
 
 
 
 
 
 
16.5
MARKET SHARE ESTIMATION
 
 
 
 
 
 
16.6
STUDY ASSUMPTIONS
 
 
 
 
 
 
16.7
RESEARCH LIMITATIONS
 
 
 
 
 
 
 
16.7.1
METHODOLOGY-RELATED LIMITATIONS
 
 
 
 
 
16.8
RISK ASSESSMENT
 
 
 
 
 
17
APPENDIX
 
 
 
 
 
447
 
17.1
DISCUSSION GUIDE
 
 
 
 
 
 
17.2
KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
 
 
 
 
 
 
17.3
CUSTOMIZATION OPTIONS
 
 
 
 
 
 
17.4
RELATED REPORTS
 
 
 
 
 
 
17.5
AUTHOR DETAILS
 
 
 
 
 
LIST OF TABLES
 
 
 
 
 
 
 
TABLE 1
EXCHANGE RATES UTILIZED FOR CONVERSION TO USD
 
 
 
 
 
 
TABLE 2
KEY PRODUCT & SERVICE LAUNCHES FOR DRUG & ALCOHOL TESTING, 2022–2025
 
 
 
 
 
 
TABLE 3
REGULATORY AUTHORITIES FOR DRUG & ALCOHOL TESTING PRODUCTS & SERVICES
 
 
 
 
 
 
TABLE 4
DRUG SCREENING MARKET: PORTER’S FIVE FORCES ANALYSIS
 
 
 
 
 
 
TABLE 5
DRUG SCREENING MARKET: ROLE IN ECOSYSTEM
 
 
 
 
 
 
TABLE 6
INDICATIVE PRICING OF DRUG SCREENING PRODUCTS & SERVICES, BY TYPE, 2024 (USD)
 
 
 
 
 
 
TABLE 7
INDICATIVE PRICING OF DRUG SCREENING PRODUCTS & SERVICES, BY REGION, 2024 (USD)
 
 
 
 
 
 
TABLE 8
DRUG SCREENING MARKET: KEY CONFERENCES & EVENTS, 2026–2027
 
 
 
 
 
 
TABLE 9
CASE 1: COMPREHENSIVE ORAL FLUID DUID TESTING PROGRAM
 
 
 
 
 
 
TABLE 10
CASE 2: HIGH-THROUGHPUT GC-MS DRUG SCREENING IN FORENSIC URINE TESTING
 
 
 
 
 
 
TABLE 11
CASE 3: ORAL FLUID DRUG TESTING IMPLEMENTATION IN A DRUG COURT PROGRAM
 
 
 
 
 
 
TABLE 12
US-ADJUSTED RECIPROCAL TARIFF RATES
 
 
 
 
 
 
TABLE 13
JURISDICTION ANALYSIS OF TOP APPLICANT COUNTRIES FOR DRUG SCREENING MARKET
 
 
 
 
 
 
TABLE 14
DRUG SCREENING MARKET: LIST OF PATENTS/PATENT APPLICATIONS
 
 
 
 
 
 
TABLE 15
INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF TOP THREE END USERS (%)
 
 
 
 
 
 
TABLE 16
KEY BUYING CRITERIA FOR TOP THREE END USERS
 
 
 
 
 
 
TABLE 17
UNMET NEEDS IN DRUG SCREENING MARKET
 
 
 
 
 
 
TABLE 18
END-USER EXPECTATIONS IN DRUG SCREENING MARKET
 
 
 
 
 
 
TABLE 19
NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
 
TABLE 20
EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
 
TABLE 21
ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
 
TABLE 22
LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
 
TABLE 23
MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
 
TABLE 24
REGULATORY SCENARIO OF NORTH AMERICA
 
 
 
 
 
 
TABLE 25
REGULATORY SCENARIO OF EUROPE
 
 
 
 
 
 
TABLE 26
REGULATORY SCENARIO OF ASIA PACIFIC
 
 
 
 
 
 
TABLE 27
REGULATORY SCENARIO OF LATIN AMERICA
 
 
 
 
 
 
TABLE 28
REGULATORY SCENARIO OF MIDDLE EAST & AFRICA
 
 
 
 
 
 
TABLE 29
DRUG SCREENING MARKET, BY OFFERING, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 30
DRUG SCREENING SERVICES MARKET: MAJOR PLAYERS & OFFERINGS
 
 
 
 
 
 
TABLE 31
DRUG SCREENING SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 32
DRUG SCREENING SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 33
DRUG SCREENING MARKET FOR LABORATORY TESTING SERVICES, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 34
DRUG SCREENING MARKET FOR ON-SITE TESTING SERVICES, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 35
DRUG SCREENING PRODUCTS MARKET: MAJOR PLAYERS & OFFERINGS
 
 
 
 
 
 
TABLE 36
DRUG SCREENING PRODUCTS MARKET, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 37
DRUG SCREENING PRODUCTS MARKET, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 38
DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 39
DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 40
DRUG SCREENING MARKET FOR BREATHALYZERS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 41
DRUG SCREENING MARKET FOR BREATHALYZERS, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 42
DRUG SCREENING MARKET FOR FUEL-CELL BREATHALYZERS, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 43
DRUG SCREENING MARKET FOR SEMICONDUCTOR BREATHALYZERS, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 44
DRUG SCREENING MARKET FOR OTHER BREATHALYZERS, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 45
DRUG SCREENING MARKET FOR IMMUNOASSAY ANALYZERS, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 46
DRUG SCREENING MARKET FOR CHROMATOGRAPHY INSTRUMENTS, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 47
DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY MODALITY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 48
DRUG SCREENING MARKET FOR HANDHELD BREATHALYZERS, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 49
DRUG SCREENING MARKET FOR BENCHTOP BREATHALYZERS, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 50
DRUG SCREENING MARKET FOR RAPID TESTING DEVICES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 51
DRUG SCREENING MARKET FOR RAPID TESTING DEVICES, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 52
BLOOD SCREENING MARKET FOR URINE TESTING DEVICES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 53
DRUG SCREENING MARKET FOR URINE TESTING DEVICES, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 54
DRUG SCREENING MARKET FOR DRUG TESTING CUPS, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 55
DRUG SCREENING MARKET FOR DIP CARDS, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 56
DRUG SCREENING MARKET FOR DRUG TESTING CASSETTES, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 57
DRUG SCREENING MARKET FOR ORAL FLUID TESTING DEVICES, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 58
DRUG SCREENING MARKET FOR CONSUMABLES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 59
DRUG SCREENING MARKET FOR CONSUMABLES, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 60
DRUG SCREENING MARKET FOR ASSAY KITS, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 61
DRUG SCREENING MARKET FOR SAMPLE COLLECTION DEVICES, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 62
DRUG SCREENING MARKET FOR CALIBRATORS & CONTROLS, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 63
DRUG SCREENING MARKET FOR OTHER CONSUMABLES, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 64
DRUG SCREENING MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 65
DRUG SCREENING MARKET FOR URINE SAMPLES: MAJOR PLAYERS & OFFERINGS
 
 
 
 
 
 
TABLE 66
DRUG SCREENING MARKET FOR URINE SAMPLES, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 67
DRUG SCREENING MARKET FOR BREATH SAMPLES: MAJOR PLAYERS & OFFERINGS
 
 
 
 
 
 
TABLE 68
DRUG SCREENING MARKET FOR BREATH SAMPLES, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 69
DRUG SCREENING MARKET FOR ORAL FLUID SAMPLES: MAJOR PLAYERS & OFFERINGS
 
 
 
 
 
 
TABLE 70
DRUG SCREENING MARKET FOR ORAL FLUID SAMPLES, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 71
DRUG SCREENING MARKET FOR HAIR SAMPLES: MAJOR PLAYERS & OFFERINGS
 
 
 
 
 
 
TABLE 72
DRUG SCREENING MARKET FOR HAIR SAMPLES, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 73
DRUG SCREENING MARKET FOR OTHER SAMPLES: MAJOR PLAYERS & OFFERINGS
 
 
 
 
 
 
TABLE 74
DRUG SCREENING MARKET FOR OTHER SAMPLES, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 75
DRUG SCREENING MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 76
DRUG SCREENING MARKET FOR CANNABIS: MAJOR PLAYERS & OFFERINGS
 
 
 
 
 
 
TABLE 77
DRUG SCREENING MARKET FOR CANNABIS, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 78
DRUG SCREENING MARKET FOR ALCOHOL: MAJOR PLAYERS & OFFERINGS
 
 
 
 
 
 
TABLE 79
DRUG SCREENING MARKET FOR ALCOHOL, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 80
DRUG SCREENING MARKET FOR COCAINE: MAJOR PLAYERS & OFFERINGS
 
 
 
 
 
 
TABLE 81
DRUG SCREENING MARKET FOR COCAINE, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 82
DRUG SCREENING MARKET FOR OPIOIDS: MAJOR PLAYERS & OFFERINGS
 
 
 
 
 
 
TABLE 83
DRUG SCREENING MARKET FOR OPIDS, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 84
DRUG SCREENING MARKET FOR AMPHETAMINES & METHAMPHETAMINES: MAJOR PLAYERS & OFFERINGS
 
 
 
 
 
 
TABLE 85
DRUG SCREENING MARKET FOR AMPHETAMINES & METHAMPHETAMINES, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 86
DRUG SCREENING MARKET FOR OTHER DRUGS: MAJOR PLAYERS & OFFERINGS
 
 
 
 
 
 
TABLE 87
DRUG SCREENING MARKET FOR OTHER DRUGS, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 88
DRUG SCREENING MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 89
DRUG SCREENING MARKET FOR DRUG TESTING LABORATORIES: MAJOR PLAYERS & OFFERINGS
 
 
 
 
 
 
TABLE 90
DRUG SCREENING MARKET FOR DRUG TESTING LABORATORIES, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 91
DRUG SCREENING MARKET FOR WORKPLACES: MAJOR PLAYERS & OFFERINGS
 
 
 
 
 
 
TABLE 92
DRUG SCREENING MARKET FOR WORKPLACES, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 93
US: DRUG SCREENING MARKET FOR WORKPLACES, BY TYPE, 2019–2026 (USD MILLION)
 
 
 
 
 
 
TABLE 94
DRUG SCREENING MARKET FOR CRIMINAL JUSTICE SYSTEMS & LAW ENFORCEMENT AGENCIES: MAJOR PLAYERS & OFFERINGS
 
 
 
 
 
 
TABLE 95
DRUG SCREENING MARKET FOR CRIMINAL JUSTICE SYSTEMS & LAW ENFORCEMENT AGENCIES, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 96
DRUG SCREENING MARKET FOR HOSPITALS: MAJOR PLAYERS & OFFERINGS
 
 
 
 
 
 
TABLE 97
DRUG SCREENING MARKET FOR HOSPITALS, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 98
DRUG SCREENING MARKET FOR DRUG TREATMENT CENTERS: MAJOR PLAYERS & OFFERINGS
 
 
 
 
 
 
TABLE 99
DRUG SCREENING MARKET FOR DRUG TREATMENT CENTERS, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 100
DRUG SCREENING MARKET FOR INDIVIDUAL USERS: MAJOR PLAYERS & OFFERINGS
 
 
 
 
 
 
TABLE 101
DRUG SCREENING MARKET FOR INDIVIDUAL USERS, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 102
DRUG SCREENING MARKET FOR PAIN MANAGEMENT CENTERS: MAJOR PLAYERS & OFFERINGS
 
 
 
 
 
 
TABLE 103
DRUG SCREENING MARKET FOR PAIN MANAGEMENT CENTERS, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 104
DRUG SCREENING MARKET FOR SCHOOLS & COLLEGES: MAJOR PLAYERS & OFFERINGS
 
 
 
 
 
 
TABLE 105
DRUG SCREENING MARKET FOR SCHOOLS & COLLEGES, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 106
DRUG SCREENING MARKET FOR OTHER END USERS: MAJOR PLAYERS & OFFERINGS
 
 
 
 
 
 
TABLE 107
DRUG SCREENING MARKET FOR OTHER END USERS, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 108
DRUG SCREENING MARKET, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 109
NORTH AMERICA: MACROECONOMIC INDICATORS
 
 
 
 
 
 
TABLE 110
NORTH AMERICA: DRUG SCREENING MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 111
NORTH AMERICA: DRUG SCREENING MARKET, BY OFFERING, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 112
NORTH AMERICA: DRUG SCREENING SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 113
NORTH AMERICA: DRUG SCREENING PRODUCTS MARKET, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 114
NORTH AMERICA: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 115
NORTH AMERICA: DRUG SCREENING MARKET FOR BREATHALYZERS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 116
NORTH AMERICA: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY MODALITY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 117
NORTH AMERICA: DRUG SCREENING MARKET FOR RAPID TESTING DEVICES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 118
NORTH AMERICA: DRUG SCREENING MARKET FOR URINE TESTING DEVICES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 119
NORTH AMERICA: DRUG SCREENING MARKET FOR CONSUMABLES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 120
NORTH AMERICA: DRUG SCREENING MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 121
NORTH AMERICA: DRUG SCREENING MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 122
NORTH AMERICA: DRUG SCREENING MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 123
US: DRUG SCREENING MARKET, BY OFFERING, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 124
US: DRUG SCREENING SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 125
US: DRUG SCREENING PRODUCTS MARKET, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 126
US: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 127
US: DRUG SCREENING MARKET FOR BREATHALYZERS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 128
US: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY MODALITY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 129
US: DRUG SCREENING MARKET FOR RAPID TESTING DEVICES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 130
US: DRUG SCREENING MARKET FOR URINE TESTING DEVICES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 131
US: DRUG SCREENING MARKET FOR CONSUMABLES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 132
US: DRUG SCREENING MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 133
US: DRUG SCREENING MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 134
US: DRUG SCREENING MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 135
CANADA: DRUG SCREENING MARKET, BY OFFERING, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 136
CANADA: DRUG SCREENING SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 137
CANADA: DRUG SCREENING PRODUCTS MARKET, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 138
CANADA: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 139
CANADA: DRUG SCREENING MARKET FOR BREATHALYZERS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 140
CANADA: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY MODALITY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 141
CANADA: DRUG SCREENING MARKET FOR RAPID TESTING DEVICES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 142
CANADA: DRUG SCREENING MARKET FOR URINE TESTING DEVICES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 143
CANADA: DRUG SCREENING MARKET FOR CONSUMABLES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 144
CANADA: DRUG SCREENING MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 145
CANADA: DRUG SCREENING MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 146
CANADA: DRUG SCREENING MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 147
EUROPE: MACROECONOMIC INDICATORS
 
 
 
 
 
 
TABLE 148
EUROPE: DRUG SCREENING MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 149
EUROPE: DRUG SCREENING MARKET, BY OFFERING, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 150
EUROPE: DRUG SCREENING SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 151
EUROPE: DRUG SCREENING PRODUCTS MARKET, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 152
EUROPE: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 153
EUROPE: DRUG SCREENING MARKET FOR BREATHALYZERS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 154
EUROPE: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY MODALITY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 155
EUROPE: DRUG SCREENING MARKET FOR RAPID TESTING DEVICES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 156
EUROPE: DRUG SCREENING MARKET FOR URINE TESTING DEVICES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 157
EUROPE: DRUG SCREENING MARKET FOR CONSUMABLES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 158
EUROPE: DRUG SCREENING MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 159
EUROPE: DRUG SCREENING MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 160
EUROPE: DRUG SCREENING MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 161
GERMANY: DRUG SCREENING MARKET, BY OFFERING, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 162
GERMANY: DRUG SCREENING SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 163
GERMANY: DRUG SCREENING PRODUCTS MARKET, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 164
GERMANY: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 165
GERMANY: DRUG SCREENING MARKET FOR BREATHALYZERS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 166
GERMANY: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY MODALITY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 167
GERMANY: DRUG SCREENING MARKET FOR RAPID TESTING DEVICES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 168
GERMANY: DRUG SCREENING MARKET FOR URINE TESTING DEVICES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 169
GERMANY: DRUG SCREENING MARKET FOR CONSUMABLES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 170
GERMANY: DRUG SCREENING MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 171
GERMANY: DRUG SCREENING MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 172
GERMANY: DRUG SCREENING MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 173
FRANCE: DRUG SCREENING MARKET, BY OFFERING, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 174
FRANCE: DRUG SCREENING SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 175
FRANCE: DRUG SCREENING PRODUCTS MARKET, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 176
FRANCE: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 177
FRANCE: DRUG SCREENING MARKET FOR BREATHALYZERS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 178
FRANCE: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY MODALITY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 179
FRANCE: DRUG SCREENING MARKET FOR RAPID TESTING DEVICES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 180
FRANCE: DRUG SCREENING MARKET FOR URINE TESTING DEVICES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 181
FRANCE: DRUG SCREENING MARKET FOR CONSUMABLES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 182
FRANCE: DRUG SCREENING MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 183
FRANCE: DRUG SCREENING MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 184
FRANCE: DRUG SCREENING MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 185
UK: DRUG SCREENING MARKET, BY OFFERING, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 186
UK: DRUG SCREENING SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 187
UK: DRUG SCREENING PRODUCTS MARKET, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 188
UK: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 189
UK: DRUG SCREENING MARKET FOR BREATHALYZERS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 190
UK: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY MODALITY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 191
UK: DRUG SCREENING MARKET FOR RAPID TESTING DEVICES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 192
UK: DRUG SCREENING MARKET FOR URINE TESTING DEVICES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 193
UK: DRUG SCREENING MARKET FOR CONSUMABLES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 194
UK: DRUG SCREENING MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 195
UK: DRUG SCREENING MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 196
UK: DRUG SCREENING MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 197
ITALY: DRUG SCREENING MARKET, BY OFFERING, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 198
ITALY: DRUG SCREENING SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 199
ITALY: DRUG SCREENING PRODUCTS MARKET, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 200
ITALY: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 201
ITALY: DRUG SCREENING MARKET FOR BREATHALYZERS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 202
ITALY: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY MODALITY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 203
ITALY: DRUG SCREENING MARKET FOR RAPID TESTING DEVICES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 204
ITALY: DRUG SCREENING MARKET FOR URINE TESTING DEVICES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 205
ITALY: DRUG SCREENING MARKET FOR CONSUMABLES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 206
ITALY: DRUG SCREENING MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 207
ITALY: DRUG SCREENING MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 208
ITALY: DRUG SCREENING MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 209
SPAIN: DRUG SCREENING MARKET, BY OFFERING, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 210
SPAIN: DRUG SCREENING SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 211
SPAIN: DRUG SCREENING PRODUCTS MARKET, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 212
SPAIN: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 213
SPAIN: DRUG SCREENING MARKET FOR BREATHALYZERS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 214
SPAIN: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY MODALITY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 215
SPAIN: DRUG SCREENING MARKET FOR RAPID TESTING DEVICES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 216
SPAIN: DRUG SCREENING MARKET FOR URINE TESTING DEVICES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 217
SPAIN: DRUG SCREENING MARKET FOR CONSUMABLES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 218
SPAIN: DRUG SCREENING MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 219
SPAIN: DRUG SCREENING MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 220
SPAIN: DRUG SCREENING MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 221
REST OF EUROPE: DRUG SCREENING MARKET, BY OFFERING, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 222
REST OF EUROPE: DRUG SCREENING SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 223
REST OF EUROPE: DRUG SCREENING PRODUCTS MARKET, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 224
REST OF EUROPE: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 225
REST OF EUROPE: DRUG SCREENING MARKET FOR BREATHALYZERS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 226
REST OF EUROPE: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY MODALITY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 227
REST OF EUROPE: DRUG SCREENING MARKET FOR RAPID TESTING DEVICES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 228
REST OF EUROPE: DRUG SCREENING MARKET FOR URINE TESTING DEVICES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 229
REST OF EUROPE: DRUG SCREENING MARKET FOR CONSUMABLES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 230
REST OF EUROPE: DRUG SCREENING MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 231
REST OF EUROPE: DRUG SCREENING MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 232
REST OF EUROPE: DRUG SCREENING MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 233
ASIA PACIFIC: MACROECONOMIC INDICATORS
 
 
 
 
 
 
TABLE 234
ASIA PACIFIC: DRUG SCREENING MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 235
ASIA PACIFIC: DRUG SCREENING MARKET, BY OFFERING, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 236
ASIA PACIFIC: DRUG SCREENING SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 237
ASIA PACIFIC: DRUG SCREENING PRODUCTS MARKET, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 238
ASIA PACIFIC: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 239
ASIA PACIFIC: DRUG SCREENING MARKET FOR BREATHALYZERS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 240
ASIA PACIFIC: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY MODALITY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 241
ASIA PACIFIC: DRUG SCREENING MARKET FOR RAPID TESTING DEVICES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 242
ASIA PACIFIC: DRUG SCREENING MARKET FOR URINE TESTING DEVICES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 243
ASIA PACIFIC: DRUG SCREENING MARKET FOR CONSUMABLES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 244
ASIA PACIFIC: DRUG SCREENING MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 245
ASIA PACIFIC: DRUG SCREENING MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 246
ASIA PACIFIC: DRUG SCREENING MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 247
CHINA: DRUG SCREENING MARKET, BY OFFERING, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 248
CHINA: DRUG SCREENING SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 249
CHINA: DRUG SCREENING PRODUCTS MARKET, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 250
CHINA: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 251
CHINA: DRUG SCREENING MARKET FOR BREATHALYZERS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 252
CHINA: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY MODALITY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 253
CHINA: DRUG SCREENING MARKET FOR RAPID TESTING DEVICES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 254
CHINA: DRUG SCREENING MARKET FOR URINE TESTING DEVICES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 255
CHINA: DRUG SCREENING MARKET FOR CONSUMABLES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 256
CHINA: DRUG SCREENING MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 257
CHINA: DRUG SCREENING MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 258
CHINA: DRUG SCREENING MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 259
JAPAN: DRUG SCREENING MARKET, BY OFFERING, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 260
JAPAN: DRUG SCREENING SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 261
JAPAN: DRUG SCREENING PRODUCTS MARKET, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 262
JAPAN: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 263
JAPAN: DRUG SCREENING MARKET FOR BREATHALYZERS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 264
JAPAN: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY MODALITY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 265
JAPAN: DRUG SCREENING MARKET FOR RAPID TESTING DEVICES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 266
JAPAN: DRUG SCREENING MARKET FOR URINE TESTING DEVICES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 267
JAPAN: DRUG SCREENING MARKET FOR CONSUMABLES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 268
JAPAN: DRUG SCREENING MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 269
JAPAN: DRUG SCREENING MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 270
JAPAN: DRUG SCREENING MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 271
INDIA: DRUG SCREENING MARKET, BY OFFERING, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 272
INDIA: DRUG SCREENING SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 273
INDIA: DRUG SCREENING PRODUCTS MARKET, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 274
INDIA: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 275
INDIA: DRUG SCREENING MARKET FOR BREATHALYZERS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 276
INDIA: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY MODALITY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 277
INDIA: DRUG SCREENING MARKET FOR RAPID TESTING DEVICES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 278
INDIA: DRUG SCREENING MARKET FOR URINE TESTING DEVICES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 279
INDIA: DRUG SCREENING MARKET FOR CONSUMABLES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 280
INDIA: DRUG SCREENING MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 281
INDIA: DRUG SCREENING MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 282
INDIA: DRUG SCREENING MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 283
AUSTRALIA: DRUG SCREENING MARKET, BY OFFERING, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 284
AUSTRALIA: DRUG SCREENING SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 285
AUSTRALIA: DRUG SCREENING PRODUCTS MARKET, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 286
AUSTRALIA: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 287
AUSTRALIA: DRUG SCREENING MARKET FOR BREATHALYZERS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 288
AUSTRALIA: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY MODALITY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 289
AUSTRALIA: DRUG SCREENING MARKET FOR RAPID TESTING DEVICES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 290
AUSTRALIA: DRUG SCREENING MARKET FOR URINE TESTING DEVICES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 291
AUSTRALIA: DRUG SCREENING MARKET FOR CONSUMABLES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 292
AUSTRALIA: DRUG SCREENING MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 293
AUSTRALIA: DRUG SCREENING MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 294
AUSTRALIA: DRUG SCREENING MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 295
SOUTH KOREA: DRUG SCREENING MARKET, BY OFFERING, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 296
SOUTH KOREA: DRUG SCREENING SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 297
SOUTH KOREA: DRUG SCREENING PRODUCTS MARKET, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 298
SOUTH KOREA: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 299
SOUTH KOREA: DRUG SCREENING MARKET FOR BREATHALYZERS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 300
SOUTH KOREA: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY MODALITY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 301
SOUTH KOREA: DRUG SCREENING MARKET FOR RAPID TESTING DEVICES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 302
SOUTH KOREA: DRUG SCREENING MARKET FOR URINE TESTING DEVICES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 303
SOUTH KOREA: DRUG SCREENING MARKET FOR CONSUMABLES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 304
SOUTH KOREA: DRUG SCREENING MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 305
SOUTH KOREA: DRUG SCREENING MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 306
SOUTH KOREA: DRUG SCREENING MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 307
REST OF ASIA PACIFIC: DRUG SCREENING MARKET, BY OFFERING, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 308
REST OF ASIA PACIFIC: DRUG SCREENING SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 309
REST OF ASIA PACIFIC: DRUG SCREENING PRODUCTS MARKET, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 310
REST OF ASIA PACIFIC: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 311
REST OF ASIA PACIFIC: DRUG SCREENING MARKET FOR BREATHALYZERS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 312
REST OF ASIA PACIFIC: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY MODALITY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 313
REST OF ASIA PACIFIC: DRUG SCREENING MARKET FOR RAPID TESTING DEVICES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 314
REST OF ASIA PACIFIC: DRUG SCREENING MARKET FOR URINE TESTING DEVICES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 315
REST OF ASIA PACIFIC: DRUG SCREENING MARKET FOR CONSUMABLES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 316
REST OF ASIA PACIFIC: DRUG SCREENING MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 317
REST OF ASIA PACIFIC: DRUG SCREENING MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 318
REST OF ASIA PACIFIC: DRUG SCREENING MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 319
LATIN AMERICA: MACROECONOMIC INDICATORS
 
 
 
 
 
 
TABLE 320
LATIN AMERICA: DRUG SCREENING MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 321
LATIN AMERICA: DRUG SCREENING MARKET, BY OFFERING, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 322
LATIN AMERICA: DRUG SCREENING SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 323
LATIN AMERICA: DRUG SCREENING PRODUCTS MARKET, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 324
LATIN AMERICA: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 325
LATIN AMERICA: DRUG SCREENING MARKET FOR BREATHALYZERS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 326
LATIN AMERICA: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY MODALITY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 327
LATIN AMERICA: DRUG SCREENING MARKET FOR RAPID TESTING DEVICES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 328
LATIN AMERICA: DRUG SCREENING MARKET FOR URINE TESTING DEVICES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 329
LATIN AMERICA: DRUG SCREENING MARKET FOR CONSUMABLES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 330
LATIN AMERICA: DRUG SCREENING MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 331
LATIN AMERICA: DRUG SCREENING MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 332
LATIN AMERICA: DRUG SCREENING MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 333
BRAZIL: DRUG SCREENING MARKET, BY OFFERING, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 334
BRAZIL: DRUG SCREENING SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 335
BRAZIL: DRUG SCREENING PRODUCTS MARKET, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 336
BRAZIL: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 337
BRAZIL: DRUG SCREENING MARKET FOR BREATHALYZERS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 338
BRAZIL: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY MODALITY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 339
BRAZIL: DRUG SCREENING MARKET FOR RAPID TESTING DEVICES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 340
BRAZIL: DRUG SCREENING MARKET FOR URINE TESTING DEVICES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 341
BRAZIL: DRUG SCREENING MARKET FOR CONSUMABLES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 342
BRAZIL: DRUG SCREENING MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 343
BRAZIL: DRUG SCREENING MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 344
BRAZIL: DRUG SCREENING MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 345
MEXICO: DRUG SCREENING MARKET, BY OFFERING, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 346
MEXICO: DRUG SCREENING SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 347
MEXICO: DRUG SCREENING PRODUCTS MARKET, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 348
MEXICO: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 349
MEXICO: DRUG SCREENING MARKET FOR BREATHALYZERS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 350
MEXICO: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY MODALITY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 351
MEXICO: DRUG SCREENING MARKET FOR RAPID TESTING DEVICES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 352
MEXICO: DRUG SCREENING MARKET FOR URINE TESTING DEVICES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 353
MEXICO: DRUG SCREENING MARKET FOR CONSUMABLES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 354
MEXICO: DRUG SCREENING MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 355
MEXICO: DRUG SCREENING MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 356
MEXICO: DRUG SCREENING MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 357
REST OF LATIN AMERICA: DRUG SCREENING MARKET, BY OFFERING, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 358
REST OF LATIN AMERICA: DRUG SCREENING SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 359
REST OF LATIN AMERICA: DRUG SCREENING PRODUCTS MARKET, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 360
REST OF LATIN AMERICA: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 361
REST OF LATIN AMERICA: DRUG SCREENING MARKET FOR BREATHALYZERS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 362
REST OF LATIN AMERICA: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY MODALITY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 363
REST OF LATIN AMERICA: DRUG SCREENING MARKET FOR RAPID TESTING DEVICES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 364
REST OF LATIN AMERICA: DRUG SCREENING MARKET FOR URINE TESTING DEVICES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 365
REST OF LATIN AMERICA: DRUG SCREENING MARKET FOR CONSUMABLES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 366
REST OF LATIN AMERICA: DRUG SCREENING MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 367
REST OF LATIN AMERICA: DRUG SCREENING MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 368
REST OF LATIN AMERICA: DRUG SCREENING MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 369
MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS
 
 
 
 
 
 
TABLE 370
MIDDLE EAST & AFRICA: DRUG SCREENING MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 371
MIDDLE EAST & AFRICA: DRUG SCREENING MARKET, BY OFFERING, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 372
MIDDLE EAST & AFRICA: DRUG SCREENING SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 373
MIDDLE EAST & AFRICA: DRUG SCREENING PRODUCTS MARKET, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 374
MIDDLE EAST & AFRICA: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY TYPE,2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 375
MIDDLE EAST & AFRICA: DRUG SCREENING MARKET FOR BREATHALYZERS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 376
MIDDLE EAST & AFRICA: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY MODALITY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 377
MIDDLE EAST & AFRICA: DRUG SCREENING MARKET FOR RAPID TESTING DEVICES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 378
MIDDLE EAST & AFRICA: DRUG SCREENING MARKET FOR URINE TESTING DEVICES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 379
MIDDLE EAST & AFRICA: DRUG SCREENING MARKET FOR CONSUMABLES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 380
MIDDLE EAST & AFRICA: DRUG SCREENING MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 381
MIDDLE EAST & AFRICA: DRUG SCREENING MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 382
MIDDLE EAST & AFRICA: DRUG SCREENING MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 383
GCC COUNTRIES: DRUG SCREENING MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 384
GCC COUNTRIES: DRUG SCREENING MARKET, BY OFFERING, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 385
GCC COUNTRIES: DRUG SCREENING SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 386
GCC COUNTRIES: DRUG SCREENING PRODUCTS MARKET, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 387
GCC COUNTRIES: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 388
GCC COUNTRIES: DRUG SCREENING MARKET FOR BREATHALYZERS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 389
GCC COUNTRIES: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY MODALITY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 390
GCC COUNTRIES: DRUG SCREENING MARKET FOR RAPID TESTING DEVICES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 391
GCC COUNTRIES: DRUG SCREENING MARKET FOR URINE TESTING DEVICES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 392
GCC COUNTRIES: DRUG SCREENING MARKET FOR CONSUMABLES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 393
GCC COUNTRIES: DRUG SCREENING MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 394
GCC COUNTRIES: DRUG SCREENING MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 395
GCC COUNTRIES: DRUG SCREENING MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 396
SAUDI ARABIA: DRUG SCREENING MARKET, BY OFFERING, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 397
SAUDI ARABIA: DRUG SCREENING SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 398
SAUDI ARABIA: DRUG SCREENING PRODUCTS MARKET, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 399
SAUDI ARABIA: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 400
SAUDI ARABIA: DRUG SCREENING MARKET FOR BREATHALYZERS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 401
SAUDI ARABIA: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY MODALITY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 402
SAUDI ARABIA: DRUG SCREENING MARKET FOR RAPID TESTING DEVICES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 403
SAUDI ARABIA: DRUG SCREENING MARKET FOR URINE TESTING DEVICES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 404
SAUDI ARABIA: DRUG SCREENING MARKET FOR CONSUMABLES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 405
SAUDI ARABIA: DRUG SCREENING MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 406
SAUDI ARABIA: DRUG SCREENING MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 407
SAUDI ARABIA: DRUG SCREENING MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 408
UAE: DRUG SCREENING MARKET, BY OFFERING, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 409
UAE: DRUG SCREENING SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 410
UAE: DRUG SCREENING PRODUCTS MARKET, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 411
UAE: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 412
UAE: DRUG SCREENING MARKET FOR BREATHALYZERS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 413
UAE: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY MODALITY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 414
UAE: DRUG SCREENING MARKET FOR RAPID TESTING DEVICES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 415
UAE: DRUG SCREENING MARKET FOR URINE TESTING DEVICES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 416
UAE: DRUG SCREENING MARKET FOR CONSUMABLES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 417
UAE: DRUG SCREENING MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 418
UAE: DRUG SCREENING MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 419
UAE: DRUG SCREENING MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 420
REST OF GCC COUNTRIES: DRUG SCREENING MARKET, BY OFFERING, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 421
REST OF GCC COUNTRIES: DRUG SCREENING SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 422
REST OF GCC COUNTRIES: DRUG SCREENING PRODUCTS MARKET, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 423
REST OF GCC COUNTRIES: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 424
REST OF GCC COUNTRIES: DRUG SCREENING MARKET FOR BREATHALYZERS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 425
REST OF GCC COUNTRIES: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY MODALITY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 426
REST OF GCC COUNTRIES: DRUG SCREENING MARKET FOR RAPID TESTING DEVICES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 427
REST OF GCC COUNTRIES: DRUG SCREENING MARKET FOR URINE TESTING DEVICES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 428
REST OF GCC COUNTRIES: DRUG SCREENING MARKET FOR CONSUMABLES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 429
REST OF GCC COUNTRIES: DRUG SCREENING MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 430
REST OF GCC COUNTRIES: DRUG SCREENING MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 431
REST OF GCC COUNTRIES: DRUG SCREENING MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 432
SOUTH AFRICA: DRUG SCREENING MARKET, BY OFFERING, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 433
SOUTH AFRICA: DRUG SCREENING SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 434
SOUTH AFRICA: DRUG SCREENING PRODUCTS MARKET, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 435
SOUTH AFRICA: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 436
SOUTH AFRICA: DRUG SCREENING MARKET FOR BREATHALYZERS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 437
SOUTH AFRICA: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY MODALITY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 438
SOUTH AFRICA: DRUG SCREENING MARKET FOR RAPID TESTING DEVICES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 439
SOUTH AFRICA: DRUG SCREENING MARKET FOR URINE TESTING DEVICES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 440
SOUTH AFRICA: DRUG SCREENING MARKET FOR CONSUMABLES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 441
SOUTH AFRICA: DRUG SCREENING MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 442
SOUTH AFRICA: DRUG SCREENING MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 443
SOUTH AFRICA: DRUG SCREENING MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 444
REST OF MIDDLE EAST & AFRICA: DRUG SCREENING MARKET, BY OFFERING, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 445
REST OF MIDDLE EAST & AFRICA: DRUG SCREENING SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 446
REST OF MIDDLE EAST & AFRICA: DRUG SCREENING PRODUCTS MARKET, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 447
REST OF MIDDLE EAST & AFRICA: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 448
REST OF MIDDLE EAST & AFRICA: DRUG SCREENING MARKET FOR BREATHALYZERS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 449
REST OF MIDDLE EAST & AFRICA: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY MODALITY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 450
REST OF MIDDLE EAST & AFRICA: DRUG SCREENING MARKET FOR RAPID TESTING DEVICES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 451
REST OF MIDDLE EAST & AFRICA: DRUG SCREENING MARKET FOR URINE TESTING DEVICES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 452
REST OF MIDDLE EAST & AFRICA: DRUG SCREENING MARKET FOR CONSUMABLES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 453
REST OF MIDDLE EAST & AFRICA: DRUG SCREENING MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 454
REST OF MIDDLE EAST & AFRICA: DRUG SCREENING MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 455
REST OF MIDDLE EAST & AFRICA: DRUG SCREENING MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 456
OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN DRUG SCREENING, JANUARY 2022–DECEMBER 2025
 
 
 
 
 
 
TABLE 457
DRUG SCREENING MARKET: DEGREE OF COMPETITION
 
 
 
 
 
 
TABLE 458
DRUG SCREENING MARKET: REGION FOOTPRINT
 
 
 
 
 
 
TABLE 459
DRUG SCREENING MARKET: OFFERING FOOTPRINT
 
 
 
 
 
 
TABLE 460
DRUG SCREENING MARKET: SAMPLE TYPE FOOTPRINT
 
 
 
 
 
 
TABLE 461
DRUG SCREENING MARKET: DRUG TYPE FOOTPRINT
 
 
 
 
 
 
TABLE 462
DRUG SCREENING MARKET: END-USER FOOTPRINT
 
 
 
 
 
 
TABLE 463
DRUG SCREENING MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS
 
 
 
 
 
 
TABLE 464
DRUG SCREENING MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS, BY REGION
 
 
 
 
 
 
TABLE 465
DRUG SCREENING MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS, BY OFFERING
 
 
 
 
 
 
TABLE 466
DRUG SCREENING MARKET: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2022– DECEMBER 2025
 
 
 
 
 
 
TABLE 467
DRUG SCREENING MARKET: DEALS, JANUARY 2022–DECEMBER 2025
 
 
 
 
 
 
TABLE 468
DRUG SCREENING MARKET: OTHER DEVELOPMENTS, JANUARY 2022–DECEMBER 2025
 
 
 
 
 
 
TABLE 469
LABCORP: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 470
LABCORP: PRODUCTS & SERVICES OFFERED
 
 
 
 
 
 
TABLE 471
LABCORP: DEALS, JANUARY 2022–DECEMBER 2025
 
 
 
 
 
 
TABLE 472
QUEST DIAGNOSTICS INCORPORATED: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 473
QUEST DIAGNOSTICS INCORPORATED: PRODUCTS & SERVICES OFFERED
 
 
 
 
 
 
TABLE 474
QUEST DIAGNOSTICS INCORPORATED: PRODUCT & SERVICE LAUNCHES, JANUARY 2022–DECEMBER 2025
 
 
 
 
 
 
TABLE 475
QUEST DIAGNOSTICS INCORPORATED: DEALS, JANUARY 2022–DECEMBER 2025
 
 
 
 
 
 
TABLE 476
ABBOTT: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 477
ABBOTT: PRODUCTS & SERVICES OFFERED
 
 
 
 
 
 
TABLE 478
ORASURE TECHNOLOGIES INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 479
ORASURE TECHNOLOGIES INC.: PRODUCTS & SERVICES OFFERED
 
 
 
 
 
 
TABLE 480
ORASURE TECHNOLOGIES INC.: DEALS, JANUARY 2022–DECEMBER 2025
 
 
 
 
 
 
TABLE 481
ALFA SCIENTIFIC DESIGNS INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 482
ALFA SCIENTIFIC DESIGNS INC.: PRODUCTS & SERVICES OFFERED
 
 
 
 
 
 
TABLE 483
THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 484
THERMO FISHER SCIENTIFIC INC.: PRODUCTS & SERVICES OFFERED
 
 
 
 
 
 
TABLE 485
THERMO FISHER SCIENTIFIC INC.: PRODUCT DEVELOPMENTS, JANUARY 2022–DECEMBER 2025
 
 
 
 
 
 
TABLE 486
THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2022–DECEMBER 2025
 
 
 
 
 
 
TABLE 487
DRÄGERWERK AG & CO. KGAA: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 488
DRÄGERWERK AG & CO. KGAA: PRODUCTS & SERVICES OFFERED
 
 
 
 
 
 
TABLE 489
DRÄGERWERK AG & CO. KGAA: PRODUCT LAUNCHES, JANUARY 2022–DECEMBER 2025
 
 
 
 
 
 
TABLE 490
LIFELOC TECHNOLOGIES, INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 491
LIFELOC TECHNOLOGIES, INC.: PRODUCTS & SERVICES OFFERED
 
 
 
 
 
 
TABLE 492
LIFELOC TECHNOLOGIES, INC.: OTHER DEVELOPMENTS, JANUARY 2022–DECEMBER 2025
 
 
 
 
 
 
TABLE 493
MPD INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 494
MPD INC.: PRODUCTS & SERVICES OFFERED
 
 
 
 
 
 
TABLE 495
OMEGA LABORATORIES, INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 496
OMEGA LABORATORIES, INC.: PRODUCTS & SERVICES OFFERED
 
 
 
 
 
 
TABLE 497
OMEGA LABORATORIES, INC.: SERVICE LAUNCHES, JANUARY 2022–DECEMBER 2025
 
 
 
 
 
 
TABLE 498
OMEGA LABORATORIES, INC.: DEALS, JANUARY 2022–DECEMBER 2025
 
 
 
 
 
 
TABLE 499
OMEGA LABORATORIES, INC.: OTHER DEVELOPMENTS, JANUARY 2022–DECEMBER 2025
 
 
 
 
 
 
TABLE 500
PREMIER BIOTECH, INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 501
PREMIER BIOTECH, INC.: PRODUCTS & SERVICES OFFERED
 
 
 
 
 
 
TABLE 502
PREMIER BIOTECH, INC.: DEALS, JANUARY 2022–DECEMBER 2025
 
 
 
 
 
 
TABLE 503
PSYCHEMEDICS CORPORATION: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 504
PSYCHEMEDICS CORPORATION: PRODUCTS & SERVICES OFFERED
 
 
 
 
 
 
TABLE 505
PSYCHEMEDICS CORPORATION: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2022–DECEMBER 2025
 
 
 
 
 
 
TABLE 506
PSYCHEMEDICS CORPORATION: OTHER DEVELOPMENTS, JANUARY 2022–DECEMBER 2025
 
 
 
 
 
 
TABLE 507
F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 508
F. HOFFMANN-LA ROCHE LTD.: PRODUCTS & SERVICES OFFERED
 
 
 
 
 
 
TABLE 509
F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2022–DECEMBER 2025
 
 
 
 
 
 
TABLE 510
SHIMADZU CORPORATION: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 511
SHIMADZU CORPORATION: PRODUCTS & SERVICES OFFERED
 
 
 
 
 
 
TABLE 512
SHIMADZU CORPORATION: PRODUCT LAUNCHES, JANUARY 2022–DECEMBER 2025
 
 
 
 
 
 
TABLE 513
SHIMADZU CORPORATION: DEALS, JANUARY 2022–DECEMBER 2025
 
 
 
 
 
 
TABLE 514
SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 515
SIEMENS HEALTHINEERS AG: PRODUCTS & SERVICES OFFERED
 
 
 
 
 
 
TABLE 516
SIEMENS HEALTHINEERS AG: PRODUCT LAUNCHES, JANUARY 2022–DECEMBER 2025
 
 
 
 
 
 
TABLE 517
SIEMENS HEALTHINEERS AG: DEALS, JANUARY 2022–DECEMBER 2025
 
 
 
 
 
 
TABLE 518
BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 519
BIO-RAD LABORATORIES, INC.: PRODUCTS & SERVICES OFFERED
 
 
 
 
 
 
TABLE 520
BIO-RAD LABORATORIES, INC.: PRODUCT ENHANCEMENTS, JANUARY 2022–DECEMBER 2025
 
 
 
 
 
 
TABLE 521
BIO-RAD LABORATORIES, INC.: DEALS, JANUARY 2022–DECEMBER 2025
 
 
 
 
 
 
TABLE 522
CAREHEALTH AMERICA CORP.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 523
ACCUSOURCEHR, INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 524
CORDANT HEALTH SOLUTIONS: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 525
ADVACARE PHARMA: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 526
ACM GLOBAL LABORATORIES: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 527
MILLENNIUM HEALTH: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 528
CLINICAL REFERENCE LABORATORY, INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 529
INTOXIMETERS: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 530
INTOXALOCK: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 531
RISK ASSESSMENT: DRUG SCREENING MARKET
 
 
 
 
 
 
LIST OF FIGURES
 
 
 
 
 
 
 
FIGURE 1
DRUG SCREENING MARKET SEGMENTATION & REGIONAL SCOPE
 
 
 
 
 
 
FIGURE 2
MARKET SCENARIO
 
 
 
 
 
 
FIGURE 3
GLOBAL DRUG SCREENING MARKET, 2023–2030
 
 
 
 
 
 
FIGURE 4
MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN DRUG SCREENING MARKET, 2022–2025
 
 
 
 
 
 
FIGURE 5
DISRUPTIONS INFLUENCING GROWTH OF DRUG SCREENING MARKET
 
 
 
 
 
 
FIGURE 6
HIGH-GROWTH SEGMENTS IN DRUG SCREENING MARKET, 2025–2030
 
 
 
 
 
 
FIGURE 7
ASIA PACIFIC TO REGISTER HIGHEST CAGR IN DRUG SCREENING MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD
 
 
 
 
 
 
FIGURE 8
EXPANDING WORKPLACE SAFETY MANDATES AND RISING SUBSTANCE ABUSE AWARENESS TO DRIVE MARKET GROWTH
 
 
 
 
 
 
FIGURE 9
DRUG SCREENING PRODUCTS MARKET IN NORTH AMERICA ACCOUNTED FOR LARGEST SHARE IN 2024
 
 
 
 
 
 
FIGURE 10
INDIA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
 
 
 
 
 
 
FIGURE 11
GROWTH RATES OF EMERGING ECONOMIES TO BE HIGHER THAN THOSE OF DEVELOPED ECONOMIES DURING FORECAST PERIOD
 
 
 
 
 
 
FIGURE 12
DRUG SCREENING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
 
 
 
 
 
 
FIGURE 13
DRUG SCREENING MARKET: PORTER’S FIVE FORCES ANALYSIS
 
 
 
 
 
 
FIGURE 14
DRUG SCREENING MARKET: VALUE CHAIN ANALYSIS (2024)
 
 
 
 
 
 
FIGURE 15
DRUG SCREENING MARKET: ECOSYSTEM ANALYSIS
 
 
 
 
 
 
FIGURE 16
TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
 
 
 
 
 
 
FIGURE 18
PATENT PUBLICATION TRENDS IN DRUG CREENING MARKET, 2015–2025
 
 
 
 
 
 
FIGURE 19
JURISDICTION & TOP APPLICANT ANALYSIS FOR DRUG SCREENING MARKET
 
 
 
 
 
 
FIGURE 20
TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) FOR DRUG SCREENING MARKET (JANUARY 2015 TO DECEMBER 2025)
 
 
 
 
 
 
FIGURE 21
MARKET POTENTIAL OF AI/GEN AI ON DRUG SCREENING ACROSS INDUSTRIES
 
 
 
 
 
 
FIGURE 22
IMPACT OF AI/GEN AI ON INTERCONNECTED & ADJACENT ECOSYSTEMS
 
 
 
 
 
 
FIGURE 23
INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS
 
 
 
 
 
 
FIGURE 24
KEY BUYING CRITERIA FOR TOP THREE END USERS
 
 
 
 
 
 
FIGURE 25
NORTH AMERICA: DRUG SCREENING MARKET SNAPSHOT
 
 
 
 
 
 
FIGURE 26
ASIA PACIFIC: DRUG SCREENING MARKET SNAPSHOT
 
 
 
 
 
 
FIGURE 27
REVENUE ANALYSIS OF KEY PLAYERS IN DRUG SCREENING MARKET, 2020–2024
 
 
 
 
 
 
FIGURE 28
MARKET SHARE ANALYSIS OF KEY PLAYERS IN DRUG SCREENING MARKET, 2024
 
 
 
 
 
 
FIGURE 29
DRUG SCREENING MARKET: BRAND COMPARATIVE ANALYSIS
 
 
 
 
 
 
FIGURE 30
EV/EBITDA OF KEY VENDORS
 
 
 
 
 
 
FIGURE 31
YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
 
 
 
 
 
 
FIGURE 32
DRUG SCREENING MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
 
 
 
 
 
 
FIGURE 33
DRUG SCREENING MARKET: COMPANY FOOTPRINT
 
 
 
 
 
 
FIGURE 34
DRUG SCREENING MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
 
 
 
 
 
 
FIGURE 35
LABCORP: COMPANY SNAPSHOT (2024)
 
 
 
 
 
 
FIGURE 36
QUEST DIAGNOSTICS INCORPORATED: COMPANY SNAPSHOT (2024)
 
 
 
 
 
 
FIGURE 37
ABBOTT: COMPANY SNAPSHOT (2024)
 
 
 
 
 
 
FIGURE 38
ORASURE TECHNOLOGIES INC.: COMPANY SNAPSHOT (2024)
 
 
 
 
 
 
FIGURE 39
THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2024)
 
 
 
 
 
 
FIGURE 40
DRÄGERWERK AG & CO. KGAA: COMPANY SNAPSHOT (2024)
 
 
 
 
 
 
FIGURE 41
LIFELOC TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2024)
 
 
 
 
 
 
FIGURE 42
PSYCHEMEDICS CORPORATION: COMPANY SNAPSHOT (2024)
 
 
 
 
 
 
FIGURE 43
F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2024)
 
 
 
 
 
 
FIGURE 44
SHIMADZU CORPORATION: COMPANY SNAPSHOT (2024)
 
 
 
 
 
 
FIGURE 45
SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 46
BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2024)
 
 
 
 
 
 
FIGURE 47
RESEARCH DESIGN
 
 
 
 
 
 
FIGURE 48
BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
 
 
 
 
 
 
FIGURE 49
RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
 
 
 
 
 
 
FIGURE 50
BOTTOM-UP APPROACH
 
 
 
 
 
 
FIGURE 51
TOP-DOWN APPROACH
 
 
 
 
 
 
FIGURE 52
CAGR PROJECTIONS FROM ANALYSIS OF MARKET DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN DRUG SCREENING INDUSTRY
 
 
 
 
 
 
FIGURE 53
CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
 
 
 
 
 
 
FIGURE 54
DATA TRIANGULATION METHODOLOGY
 
 
 
 
 
 

 

Methodology

The study involved five major activities to estimate the current size of the drug screening market. Exhaustive secondary research was done to collect information on the market and its different subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. Thereafter, market breakdown and data triangulation procedures were used to estimate the market size of the segments and subsegments.

Secondary Research

In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for the study of the drug screening market. It was also used to obtain important information about the top players, market classification, and segmentation according to industry trends to the bottom-most level, geographic markets, and key developments related to the market. A database of the key industry leaders was also prepared using secondary research.

Primary Research

Extensive primary research was conducted after acquiring basic knowledge about the global drug screening market scenario through secondary research. Several primary interviews were conducted with market experts from both the demand side (Hospital directors, Hospital Vice Presidents, Department heads, and Critical care specialists ) and supply side (such as C-level and D-level executives, technology experts, product managers, marketing and sales managers, among others) across five major regions North America, Europe, the Asia Pacific, Latin America, Middle East, and Africa. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.

The following is a breakdown of the primary respondents:

BREAKDOWN OF PRIMARY PARTICIPANTS:

Drug Screening Market
Size, and Share

Note 1: Others include sales managers, marketing managers, and product managers.
Note 2: Tiers of companies are defined on the basis of their total revenues in 2023. Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million.

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the total size of the drug screening market. These methods were also used extensively to estimate the size of various subsegments in the market.

 The research methodology used to estimate the market size includes the following:

Drug Screening Market Top Down and Bottom Up Approach

Data Triangulation

After arriving at the overall market size using the market size estimation processes, the market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and sub-segment, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the drug screening market.

Market Definition

Drug and alcohol testing or drug screening refers to testing individuals for illegal abuse of drugs (including legal drugs such as prescription drugs) through the use of biological samples, such as urine, oral fluids/saliva, hair, blood, and sweat.

Key Stakeholders

  • Drug screening product & solution providers (Including immunoassay kit manufacturers, confirmatory testing technology providers, breathalyzer and oral fluid testing device developers, rapid test and POCT vendors)
  • Drug screening service providers (including Clinical laboratories, reference labs, forensic toxicology labs, workplace testing providers, on-site/mobile testing service companies)
  • Healthcare providers (Hospitals, emergency departments, trauma centers, outpatient clinics, rehabilitation centers, pain management clinics, mental health and addiction treatment facilities)
  • Workplace & employer organizations
  • Law enforcement & public safety agencies
  • Research & development (R&D) companies
  • Judicial & legal system stakeholders
  • Government & regulatory authorities
  • Sports organizations & anti-doping agencies
  • Payers & insurers
  • Patients, employees & tested individuals
  • Substance abuse treatment & rehabilitation providers
  • Research & development (R&D) organizations
  • Venture capitalists & private equity firms
  • Advocacy groups & professional associations
  • Investors & financial institutions
  • Medical research laboratories & clinical trial organizations
  • Academic institutions & training centers   
  • Technology & instrumentation providers
  • Laboratory information & data management providers
  • Sample collection & logistics providers
  • Quality assurance, accreditation & certification bodies
  • Consulting, training & compliance service provider
  • Data analytics & emerging technology developers

Report Objectives

  • To define, describe, and forecast the global drug screening market based on offering, sample type, drug type, end user, and region
  • To provide detailed information regarding the major factors (such as drivers, restraints, opportunities, and challenges) influencing market growth
  • To strategically analyze micro-markets with respect to individual growth trends, prospects, and contributions to the overall drug screening market
  • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To strategically analyze the market structure profile of the key players of the drug screening market and comprehensively analyze their core competencies
  • To forecast the size of the market segments with respect to five regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
  • To track and analyze competitive developments such as product launches and enhancements, investments, partnerships, collaborations, acquisitions, expansions, product approval, and alliances in the drug screening market during the forecast period.

Available customizations:

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:
  • Product Analysis: Product matrix, which gives a detailed comparison of the product portfolios of each company.
  • Geographic Analysis:  Further breakdown of Latin America, Europe,  and the Middle East & Africa drug screening into specific countries

 

Personalize This Research

  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
Request A Free Customisation

Let Us Help You

  • What are the Known and Unknown Adjacencies Impacting the Drug Screening Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
Customized Workshop Request

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Get 10% Free Customisation

TESTIMONIALS

Growth opportunities and latent adjacency in Drug Screening Market

avtar

Chase

Apr, 2026

We are defining our market strategy. Does the report provide actionable insights for market entry and competitive positioning?.

avtar

Ryder

Apr, 2026

How is microbiome data being integrated into drug screening and biomedical research for better therapeutic outcomes?.

avtar

Finn

Apr, 2026

How are AI and biomarker research driving advancements in drug discovery and precision medicine applications?.

avtar

Eric

Apr, 2026

How is medicinal chemistry supporting advancements in drug screening and molecular-level healthcare research?.

avtar

Ryan

Apr, 2026

Could you provide detailed insights on oral fluid drug testing market trends, segmentation, and adoption across Europe, especially in law enforcement and security applications?.

avtar

Caspian

Apr, 2026

With workplace drug testing becoming more regulated, how do you see organizations balancing compliance costs with operational efficiency, especially for large-scale screening programs?.

avtar

Elio

Apr, 2026

From a buyer’s perspective, what are the biggest barriers to adopting advanced drug and alcohol screening technologies in emerging markets?.

avtar

Luca

Apr, 2026

How do you assess the ROI of implementing random drug screening programs versus pre-employment testing alone?.

avtar

Avery

Apr, 2026

There’s growing concern around data privacy and accuracy in drug testing. How can companies build trust while scaling these solutions?.

avtar

Theo

Apr, 2026

Looking ahead, what emerging opportunities do you see shaping the future of the drug and alcohol screening market?.

Show More
DMCA.com Protection Status
popup img